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Stonustoxin (Stonefish National University of Singapore, SNTX) is a 148kDa, dimeric 
lethal factor isolated from stonefish Synanceja horrida venom that exhibits a multitude of 
activity including species-specific haemolysis and platelet aggregation, edema-induction, 
hypotension, endothelium-dependent vasorelaxation, and inhibition of neuromuscular 
function in the mouse hemidiaphragm and chick biventer cervicis muscle (Low et al., 
1993; Khoo et al., 1995; Chen et al., 1997; Sung et al., 2002). In this thesis, the potent 
vasorelaxing effect of SNTX that leads to marked hypotension and death in victims was 
investigated.  
 
SNTX was purified according to the method of Poh et al., 1991 with a change in the 
column size and flow-rate used for the anion-exchange chromatography part of the 
purification process that led to a decrease in purification time. Organ bath studies with 
2mm, endothelium-intact, precontracted rat thoracic aortic rings showed that SNTX (10-
640ng/ml) progressively causes vasorelaxation that was inhibited by L-NG-nitro arginine 
methyl ester (L-NAME). This confirmed findings by Low et al., 1993 and Sung et al., 
2002 that nitric oxide (NO) is a gaseous mediator of SNTX-induced vasorelaxation.  
 
The involvement of hydrogen sulfide (H2S) working in synergy with NO in SNTX-
induced vasorelaxation was examined. H2S, a well known toxic gas associated with many 
industrial fatalities (Burnett et al., 1977; Guidotti, 1994; Sydner et al., 1995) was found 
to be an endogenously generated smooth muscle relaxant that may work in synergy with 
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NO (Hosoki et al., 1997). Since SNTX causes vasorelaxation, H2S could possibly be a 
mediator of SNTX’s effect. Using D, L-proparglyglycine (PAG) and β-cyano-L-alanine 
(BCA), both inhibitors of cystathionine-γ-lyase (CSE) which is the main enzyme 
responsible for H2S production in the vascular system showed that H2S has a role in 
SNTX-induced vasorelaxation of precontracted aortic rings. Use of L-NAME in 
conjuction with PAG or BCA showed a greater inhibitory effect than when each inhibitor 
was used individually thus suggesting that H2S may possibly work synergistically with 
NO to bring about SNTX-induced vasorelaxation. To date, this is the first report on the 
involvement of H2S working together with NO to mediate a toxin’s biological effect. 
Interestingly, as an attempt to reverse the inhibitory effect of PAG or BCA on SNTX-
induced vasorelaxation, an unexpected transient increase in tone of resting rat thoracic 
aortic rings was observed with 1mM L-cysteine.   
 
The role of the SNTX B30.2 domains in SNTX-induced vasorelaxation was also 
investigated. SNTX shows no significant homology to other proteins except that it 
possesses a novel B30.2 domain in each of its subunit that is present in a rapidly growing 
family of proteins with diverse functions and cellular locations (Henry et al., 1998). 
Currently, little is known about the structure and function of this domain. Expression and 
purification of recombinant Glutathione-S-transferase fusion proteins from E. coli BL21 
was met with co-expression of chaperonin GroEL and aggregation of fusion proteins as 
inclusion bodies. In future, more work can be done to improve protein yields and purity 
in addition to screening the B30.2 domains for other biological functions that SNTX 
possesses. 
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1.1 GENERAL INTRODUCTION 
 
Different life forms on this earth are constantly evolving to enhance their survival. 
From bacteria and flagellates to plants and animals in vastly different habitats, many 
have developed specialized structures that produce venoms and toxins that function as 
defensive and/or offensive tools against predators and preys (Figure 1). These 
chemical tools are highly effective, i.e. in the pharmacological sense; they possess 
very rapid, potent and specific mechanisms of action. Throughout history, fatalities 
associated with such poisonings have created an interest in toxin research. Scientists 
hoped that by finding out the mechanisms of action of toxins, they will be able to 
elucidate a cure for poisonings and envenomations. In the process, it was discovered 
that toxins can also be useful in therapeutics and scientific research (Table 1). 
Botulinum toxin has been used clinically for cosmetic purposes to reduce wrinkles. In 
addition, cholera toxin has also been useful in the understanding of the mechanism of 
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Figure 1. Pictures of poisonous and venomous organisms. (a) Rattlesnake, (b) 
Platypus, (c) Honey bee, (d) Tarantula, (e) Poison dart frog, (f) Box jellyfish, (g) 
Puffer fish, (h) Foxglove 
 
(a)   (b)  
(c)   (d)  
(e)   (f)  
(g)   (h)  
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Table 1. Toxins from various organisms - Mechanisms of actions and therapeutic and scientific uses. 





















Botulism Toxin produced by bacteria binds to 
receptors on presynaptic membrane 
of motor neurons associated with 
peripheral nervous system. 
Proteolysis of target proteins in 
these neurons inhibits the release of 
acetylcholine, thereby preventing 
muscle contraction. 
 
BoNT/A and E target synaptosomal-
associated protein SNAP-25. 
 
BoNTs/B, D, F, and G cleave 
vesicle associated membrane protein 
and synaptobrevin. 
 
BoNT/C hydrolyzes syntaxin and 
SNAP-25. 
 
BoNT/A – Used for 
Blepharospams, Strabismus 
and also cosmetically to 
reduce deep wrinkles caused 
by contraction of facial 
muscles. 
Singh et al., 
1995; Schiavo 





















water and food. 
Cholera Toxin Cholera Bacteria multiplies in intestinal 
epithelial cells and produces an 
enterotoxin that binds irreversibly to 
epithelial cells, thereby stimulating 
the production of cyclic AMP which 
changes cell permeability, leading to 
the secretion of water and 
electrolytes into the intestinal 
lumen. 
 
Incorporated into human 
vaccines because of its 
adjuvant properties. 
 
Used for understanding 
mechanism of adenylate 
cyclase activation and the 














Oral  Ricin Diarrhoea Ricin binds specifically to cell 
surface galactosides of the intestinal 
wall. It then enters the cytosol and 
inhibits protein sythesis by 
specifically and irreversibly 
inactivating eukaryotic ribosomes. 
Part of the Ricin protein is 
used in the production of 
RTA-immunotoxins.  
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Digestive distress occurs as a result. 
 
immunotoxins was used 
successfully to destroy T 
lymphocytes in bone marrow 
taken from histocompatible 
donors. This reduces 
rejection of the donor bone 
marrow, a problem called 
"graft-vs-host disease" 
(GVHD). In steroid-resistant, 
acute GVDH situations, 
RTA-immunotoxins helped 
alleviate the condition. 
 
Also, in autologous bone 
marrow transplantation, a 
sample of the patients own 
bone marrow is treated with 
anti-T cell immunotoxins to 
destroy malignant T-cells in 











Oral Digitoxin Heart failure on 
overdose 
Digitoxin inhibits Na+/K+-ATPase 
and results in an increase in 
intracellular Na+ concentration. This 
increased Na+ concentration inhibits 
the Na+/Ca2+-exchanger. Inhibiting 
this exchange system results in less 
Ca2+ being extruded from the cell 
and, therefore, results in an 
increased intracellular Ca2+ 
concentration. More Ca2+ ions 
available for the contraction 
mechanism enables an increased 
force of contraction 
Congestive heart failure, 
atrial fibrillation, severe 
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The stonefish S. horrida belongs to the family Scorpaenidae which is comprised of a 
large array of fish characterized by their ability to envenomate with various types of 
specialized spines. This group of fish is responsible for the second most common 
piscine envenomation after stingrays. Included in the family are 3 genera 
characterized by their venom organ structure and toxicity – Pterosis (e.g. lionfish, 
zebrafish, and butterfly cod), Scorpaena (e.g. scorpionfish, bullrout, and sculpin) and 
Synanceja (e.g. stonefish) (Figure 2).  
 
Within the genus Synanceja, there are 10 species as recorded in FishBase 
(http://www.fishbase.org/home.htm), a relational database developed at the 
WorldFish Center in collaboration with the Food and Agriculture Organization of the 
United Nations and other partners. These species include S. horrida, S. verrucosa, S. 
platyrhyncha, S. alula, S. nana, S. asteroblepa, S. erosa, S. uranoscopa, Erosa 
daruma, and Pseudosynanceia melanostigma. Of these species, only S. horrida and S. 
verrucosa have been studied. In addition, S. trachynis as described by Endean (1961) 
has an ambiguous identity and is thought by some to be actually S. horrida. Studies 
have also been carried out on S. trachynis. 
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Figure 2. Pictures showing the 3 genera of the Scorpinaedae family. (a) Lionfish 
(genus Pterois volitans) have long, slender spines with small venom glands, and they 
have the least potent sting of the Scorpaenidae family. (b) Scorpionfish (genus 
Scorpaena) has shorter, thicker spines with larger venom glands than lionfish do, and 
they have a more potent sting. (c) Stonefish (genus Synanceia) have short, stout 
spines with highly developed venom glands, and they have a potentially fatal sting. In 








Chapter 1 Introduction 
 
29 
1.2.2 NATURAL HABITAT 
 
S. horrida is widely distributed in the waters around Singapore, Malaysia, Indonesia, 
and as far as India and South Africa (Khoo, 2002). It is often found well camouflaged 
in rock crevices and half buried in sand and mud with only its mouth and eyes fully 
exposed. The coloring and shape of the stonefish covered by algae make them 
excellent ambush predators.  
 
1.2.3 STRUCTURAL FEATURES 
 
1.2.3.1 GROSS ANATOMY 
 
Two species of the stonefish S. horrida and S. verrucosa exist in Australian waters 
and McKay (1987) has devised a method to distinguish them based on facial features 
and eye position. A simple identification key is shown in Figure 3 (McKay, 1987; 
Gwee et al., 1994). 
 
The venom apparatus of the S. horrida consists of enlarged venom glands that adhere 
closely to the short, stout and thick 13 dorsal spines, 2 pelvic and 3 anal spines 
(Gopalakrishnakone and Gwee, 1993; Gwee et al., 1994; Low, 1995) (Figure 4). A 
loose integumentary sheath that covers each dorsal spine is pushed down during 
envenomation to compress upon the venom glands such that venom is involuntarily 
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Figure 3. Identification key for S. horrida and S. verrucosa differentiation (adapted 
from Gwee et al., 1994).  
 
IDENTIFICATION KEY 
Body with wart-like tubercles 
 
Without sunken cheeks      With sunken cheeks 
   
      Cobbler Fish     Stonefish 
      (Gymnapisters marmoratus) 
      S. horrida  S. verrucosa 
   Eyes small, elevated on a bony,     Eyes small, not greatly  
   saddle-like depression behind     elevated, saddle-like 
   cheek, pit-deep and more than    depression, shallow. 
   twice the width of eye.      Cheek pit less than 
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Figure 4. Pictures of S. horrida showing its hypothermic needle-like dorsal spines. 
(Pictures adapted from Australian Museum Archives). 
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expelled through the spines. The anal and pelvic spines are completely enclosed by 
their integumentary sheath and appear as non-functional venom organs (Low, 1995).  
 
1.2.3.2 MICROSCOPIC OBSERVATIONS 
 
The structure of the venom gland of S. horrida has been studied using light 
microscopy, and transmission and scanning electron microscopy (Gopalakrishnakone 
and Gwee, 1993). The glands were covered with a fibrous capsule which divided the 
glandular tissue into many septa which carried numerous nerves and blood vessels. 
Two venom gland cells are apparent.  In particular, the venom secreting cell (Type I) 
is unique and completely different from any other venom-secreting cells described so 
far in snakes (Gopalakrishnakone 1985a, 1986; Gopalakrishnakone and Kochva, 
1990), scorpions (Gopalakrishnakone, 1985b) or spiders (Gopalakrishnakone, 1987).  
 
The Type I cells do not have any features of a protein-secreting cell such as Golgi 
apparatus, or rough endoplasmic reticulum. The presence of vacuoles of varying size, 
accompanied by the presence of glandular material of different electron densities in 
varying amounts suggest that these are various stages in the maturation of the Type I 
glandular cell. The whole Type I cell completely transforms into granules, suggestive 
of a holocrine type of secretion. The type II cells, which are much fewer in number, 
showed a vacuolated appearance, and some vacuoles contained electron dense 
globular granules which are much larger than the granules seen in Type I cells. Even 
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the Type II cells did not show any characteristic features of secretory cells, as in the 
case of Type I cells.  
 
Scanning electron microscope confirmed that the secretory mechanism is holocrine. 
The breakdown of cell membrane was clearly seen and the secreted granules were 
membrane bound. It is possible that the Type I cells contribute most of the venom 
components, with some contribution from the Type II cell. This glandular model 
appears to be very different from snakes, scorpions, and spiders. Further studies are 
needed to elucidate the exact secretory granules which are involved in venom 
production in S. horrida.  
 
1.2.4 ENVENOMATIONS & TREATMENT 
 
Several interesting names have been given to the stonefish and include Ikan Hantu 
(Devil fish), the Warty Ghoul and Nohu (the Waiting One). Generally, stonefish are 
only dangerous if accidentally stepped on. The venom apparatus is used for defense 
only and never to get food. Wounds produced by the hypodermic needle-like dorsal 
spines of the fish (Figure 4) may be small but are sometimes fatal because of the 
discharge of extremely potent venom into the victim. Severity of the symptoms of 
envenomation is related to the depth of penetration of the spines and the number of 
spines involved.   
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Envenomation by stonefish is typified by a wide array of responses including fever, 
sweating, nausea, excruciating pain at wound sites, tremendous swelling and death of 
tissues, respiratory difficulties due to pulmonary edema, hypotension, bradycardia, 
arrhythmia, paralysis, convulsions and death (Phoon & Alfred, 1965; Saunders et al., 
1962). In spite of these, stonefish is also known to be a delicacy (Khoo, 2002).  
 
Some of the treatments for envenomation as recommended by eMedicine 
(http://www.emedicine.com/ ) include:  
 
1. Prevent movement of the affected part. 
2. Gentle removal of visible spines to prevent further penetration and breakage, 
meanwhile recognizing their potential for further envenomation. 
3. Apply appropriate analgesia if needed and irrigate the wound copiously.  
4. Apply direct pressure to control excessive bleeding. 
5. Immerse the injured site in warm water water (upper limit of 114 °F or 45 °C) 
in order to inactivate the thermolabile components of the venom that might 
otherwise cause a severe systemic reaction (Be careful not to inflict thermal 
burns to insensate limb).  
6. Look for broken spines. Apply adjunctive regional or local anesthesia for 
debridement of embedded spines when they are in proximity to joints, nerves, 
or vessels. Embedded structures should be pulled straight out with forceps to 
avoid breaking them.  
Chapter 1 Introduction 
 
35 
7. Treatment for anaphylaxis. Tetanus prophylaxis using epinephrine and 
antihistamines is indicated in all patients who have experienced traumatic 
marine injury and who have insufficient or uncertain immunization histories. 
8. Recognition of serious systemic symptoms and prompt institution of 
appropriate life-saving procedures, such as cardiopulmonary resuscitation 
(CPR) and advanced cardiac life support (ACLS) procedures are rarely 
indicated but always take absolute precedence 
9. Antivenom administration. Stonefish antivenin from Australia's 
Commonwealth Serum Laboratories (CSL) is recommended only for 
predilution intramuscular usage. However, for serious envenomations, this 
route may not be ideal because of erratic absorption. Following dilution, a 
slow intravenous administration may be preferable: 1 ampule (2000 U) for 
every 1-2 punctures, up to 3 ampules for more than 4 punctures. Antivenin 
should be diluted in 50-100 ml isotonic sodium chloride solution and run 
through at least 20 minutes. As this is hyperimmunized equine antisera, there 
are risks of allergic reaction and serum sickness in the recipient. Skin testing 
and/or pretreatment should precede administration. Rather than skin testing, 
Australian sources tend to recommend pretreatment with subcutaneous 
epinephrine and an intramuscular antihistamine, adding an intramuscular 
corticosteroid for known hypersensitivity. 
10. Ultrasound and plain radiographs to help locate retained fragments. Retained 
fragments should be removed as they act as foreign bodies, causing 
Chapter 1 Introduction 
 
36 
inflammation and eventually becoming encapsulated into granulomata, which 
may lead to delayed healing and secondary infection. 
 
1.2.5 S. HORRIDA VENOM & ITS BIOLOGICAL ACTIVITIES 
 
As with the venoms of other organisms, S. horrida venom is a complex mixture. The 
fresh venom is opalescent and has a pH of 6.8 (Poh et al., 1991). The protein content 
accounts for 20% of the dry weight of the lypophilized venom (Poh et al., 1991). The 
LD50 (i.v.) of the venom was found to be 0.3µg/g in mice (Khoo et al., 1992). 
Extrapolated to a 60kg human, this value suggests that 18mg venom would cause 
death. This dose could be relayed from six intact spines (Khoo et al., 2002). A lethal 
dose of the venom caused convulsive movements, respiratory arrest, urination, 
hypersalivation and death within 3-30min of injection (Poh et al., 1991).  
 
The venom of S. horrida was screened to check the biological activities it possesses 
(Khoo et al., 1992). It exhibited edema-inducing, species-specific hemolysis and high 
hyaluronidase activities. Weak thrombin-like, alkaline phosphomonoesterase, 5’-
nucleotidase, acetylcholinesterase, phosphodiesterase, arginine esterase, and arginine 
amidase activities were also detectable. Recalcification clotting time, prothrombin, 
and kaolin-cephalin clotting ties were increased 1.7, 2.3 and 2.4-fold respectively. Its 
effects on uptake and stimulation of neurotransmitter synthesis and release in rat brain 
synaptosomes were also evaluated. In the presence of 100ug venom, uptake of 
[methyl-3H]-choline in rat brain synaptosomes was inhibited 70%, while that of 4-
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amino-n-[U-14-c] butyric acid was inhibited 20%. The toxin also stimulated the 
release of [3H]-acetylcholine from the synaptosomes. Currently, two proteins have 
also been isolated from the venom, namely Stonustoxin (Poh et al., 1991) and 
hyaluronidase (Poh et al., 1992). 
 
1.2.6 STONUSTOXIN (SNTX) – A MULTIFUNCTIONAL LETHAL PROTEIN 




Stonustoxin (Stonefish National University of Singapore, SNTX) was purified to 
homogeneity from S. horrida venom via a two-step procedure using Sephacyl S-200 
High Resolution (HR) gel filtration chromatography and DEAE Bio-Gel A anion 
exchange chromatography (Poh et al., 1991). The first process resolved the venom 
into three major fractions, of which only one exhibited lethal activity. This lethal 
fraction was then subjected to anion exchange chromatography which yielded four 
fractions of which one shows lethal activity. This lethality-inducing fraction gave 
only a single protein band in a 5% non-denaturing polyacrylamide gel. This protein 
was thus designated SNTX. High performance size exclusion liquid chromatography 
showed that SNTX has a native molecular weight of 148kDa. Reducing and non-
reducing SDS-polyacrylamide gel electrophoresis revealed that SNTX is made up of 
two subunits, SNTX-α and SNTX-β with molecular weights of 71kDa and 79kDa 
respectively (Ghadessey et al., 1996). The subunits are postulated to associate via 
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non-covalent intra-chain linkages not involving disulfide linkages. In addition, it was 
found that SNTX has an isoelectric point of 6.9 (Poh et al., 1991). The purified 
SNTX has an LD50 of 0.017µg/g which is 22-fold more potent than that of the crude 
venom.  
 
1.2.6.2 cDNA CLONING & CHARACTERIZATION 
 
cDNA clones encoding SNTX-α and SNTX-β had been isolated and sequenced from 
a S. horrida venom gland cDNA library (Ghadessey et al., 1996) (Figure 5 & 6). In 
addition, the genomic region which encodes SNTX-β was found to possess an intron 
(Ghadessey et al., 1994). The SNTX subunits lack typical N-terminal signal 
sequences commonly found in proteins that are secreted via the endoplasmic 
reticulum Golgi apparatus pathway, indicating the possibility of it being secreted by a 
non-classical pathway (Ghadessey et al., 1996). Previously, it has been found that the 
venom secreting cells of S. horrida lack features of a protein-secreting cell such as 
Golgi apparatus, or rough endoplasmic reticulum (Gopalakrishnakone amd Gwee, 
1993) that are present in snakes (Gopalakrishnakone 1985a, 1986;  
Gopalakrishnakone and Kochva, 1990), scorpions (Gopalakrishnakone, 1985b) or 
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Figure 5. S. horrida SNTX-α mRNA (2171 bp), complete cds (NCBI: U36237). 






















1  gaagtcagga cgactctcac aactcagcag atctacacaa cttcatcagg gttgcaggca  
61  tgtcttcaga tttggtaatg cctgctctgg gtcgaccttt cacccttggg atgctgtatg  
121  atgctcgcag agagaaactg atcccaggtt tctcattatt tggtgatgaa actctacaaa  
181  aatatcaatc aagtaacgct caacgcagca gtgaattcaa aatcgttgct tctgattcca  
241  ctgagtccaa gtcctctgcg atggatattg aagcttctct tggagtcagt ttcctgggag  
301  gactggttga agttggagga tctgccaagt atctcaacaa tacgaagaaa taccagaatc  
361  agagcagagt tacactcaag tacaaagcta ccaccgtcta taaacagttc acagcacctc  
421  ctgggactgt gacagtgcaa gaaacagcta ttactgagaa gggattggca acacatgtag  
481  taacaagcat cctttatggg gcaaatgctt tctttgtgtc tgacagtgac aaggtagagg  
541  ataccaacct tcaggacatc cagggcaaaa tggaagccgc aataaagaag attcctacga  
601  ttagtattga ggggtctgca tctgtccaac tgactgatga agaaaagtct ctggccagca  
661  atctctcctg caagtttcat ggagacttcc ttcttgaaag cctccctaca acgtttgaag  
721  atgcagtgaa gacctaccag acacttccaa cacttattgg agaagacgga gccaattcag  
781  ttccaatgaa ggtctggctg gcacccttga agagctataa ttctaaagcc caacagctga  
841  tccaagagat caatgttagt aaagtgagaa ggattcacac taccttagaa gagttgcata  
901  aactgaagag gagagccaat gaagccatgg atgtcaaact tgtgcaacga attccattga  
961  ttcatgacaa gattagcaat ttccaacaga tatttcagga ttacatgctt accgtgcaaa  
1021  agaaaattgc agagaaactt ccactggttc gagcaggtac agaaagtgag cagtcattgc  
1081  agaagataat tgatgacaga gcccagtcac cattcagcaa tgaaaaagtg agcaagtggc  
1141  tggatgccgt agagagagaa atcgctgtct taaagtcctg tgcaggcatg gttgagggaa  
1201  cacaggcaaa atttgtctca aatcagacag agttggacag agaggttctt gttggaaagg  
1261  taaagcatgc tgtgtgcttt attttcacct cagtggaacg caatgatcct taccttaaag  
1321  tgttgtccga ctattgggaa tcaccccctt caaataatgc aaaggatgtt gcgccatcta  
1381  ctgaagacaa gtggtgtttc tccactgagg tggtactcaa aatgcaacaa agagcccaaa  
1441  cattttgtga tcatgtcaac gattttgaga aaagcagaaa cgttggtttc tttatcacag  
1501  ccttggaaaa tggaaaattc caaggagcaa gcatctacta ttacaaggag ggcagtctgg  
1561  ccactcagga cttcacattc cctcgcatgc cttttgtgca gggttacaaa aagagaagtg  
1621  atttactttg gtatgcctgt gacctcacct ttgaccgaaa caccataaac aactggatct  
1681  ctctttctga caacgataca tttgcagcct ctgagcatgg aaaacggcag aactatccaa  
1741  aacacccaga acgttttgtt agttttaatc aggtgttgtg caatgagggg ctgatgggga  
1801  aacattactg ggaggtggag tggaacggat acattgatgt aggtattgct tacatttcca  
1861  tccccaggaa agaaattgac tttgcgagtg ctttcgggta caatacctat tcctgggttt  
1921  taagctataa tcccaaaatt ggatacatcg aaaggcataa aaaaagagaa tataatgtca  
1981  gggcgcccaa tccaggcttt aaacgactag gactgtttct cgattggcgt tatggcagta  
2041  tatctttcta tgctgtctcc tctgatgaag tgcaccatct tcacaccttc aaaaccaaat  
2101  ttactgagcc tgtttatccg gccttcagta tcgggcctgc cggtaaccac ggaactctca  
2161 gattacttta a  
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Figure 6. S. horrida SNTX-β mRNA (2740bp), complete cds (NCBI: U32516). 






















1  gaagtcagga agactcctac tgaactcaac tgatctgcac aagttcatca ggttggagtc 
61  atgccttcag atatcttggt ggtggctgct ctgggccgac cgttcacgct ggggatgctc 
121  tatgacgctc gaaatgataa actgatccca gggttcacat tgtgggaaga tgaagttata 
181  gaagagagca cacttgaaag cagtcagccc agcagtgcat ttgaaattat tgcatctgat 
241  tctactgatg acaagtcttc tctgatggat attgaagcat ctctgaaagc cagtttcctg 
301  ggtggactgg tagaagttgg aggatcagcc aagtatctga ataatcagaa gaaattcaag 
361  aatcagagtc gagtgactct tcagtacaaa gctaccacta gcttcaaaca gctgatgact 
421  aatcttggaa ccaaacatgt agaatattct gaattatttg agaacatcca ggcaactcat 
481 gtagtgatag ggatccttta tggggccaat gccttctttg tctttgacag taacaaagtg 
541  gattcaacca atgttcagga aatccagggc caaatggaag ctgtaataaa gaagattcct 
601  tcagttgaaa tctcagggaa agcttctgtc cagctaaccg gtgaggaaac tgatataacc 
661  aacagctttt cctgtgaatt ccatggggac ttctttctca ctaccaaccc tacaactttt 
721  gaggatgcag ttaaaacata ccagcaactt ccacaaatga tggggaaaga caatgctgtc 
781  ccaatgacgg tctggctcgt gccaatggta aatttttatt ctgaagcacc tcaactgatg 
841  gctgatagca gcactccaat acttaggaag gttcgcaaca ctctggaagc catagtgcaa 
901  gttcaaatga gatgcaacga tgcactggat gaccccacag tgaacctgtt cacagaggtt 
961  caaaagaagt tgagcgattt ccaaaaaatt tgtgatgatc atatgtcaaa actccaggcg 
1021  acgattgcga agaaactttt tgccatccgg agtggagatg aagatgaaag tgccttactg 
1081  aacctttttg aagaaaacct tcaatcacca ttcaacatcg aaagcctaaa catgtggatg 
1141  gagtttgaag aaagagagat caatgtcctc aggtcctgca tggatatttt aacgaaagca 
1201  aaacctaagg ttatttttaa tcaaggtgta ctttttaaag gactttatga ttcaaaagta 
1261  aagcatgctt tgtgctatgt ctttaccaat gtgacaaaga atgatgtctt cctgaacgtg 
1321  ttaaatgagt tcttggattc acctcaaagc agaccaaaga aactcagacc ttcaccaaaa 
1381  gactactggt atagctatga tgacatacca gagacgatga gggaaaaagc ttaccttttc 
1441  cgcaaccttg ccaaagagat gaacaaccgc tgtgtccatt tctttgtaac ggctatacat 
1501  aatccaaagc aagaaggagc aggcatccac tactacaggg agagcatcca gatcattgat 
1561  gagtttacaa aaccttacat gcctggtgtg gagagcataa aagacagaag agagttacag 
1621  tggtatgact gtgagctcac cctggaccca gaaacagcac accaggtcct gactctgtcc 
1681  gagggcaaca aaaaggcagt ttcagggaat acgaagtcac ccaccgatca cctagagaag 
1741  ttcagccact ttcagcaggt gatgtgcacc aaggggctga gtgggcgcca ttactgggag 
1801  ttagagtggt ctggttacgt tggtgcaggt gtcacatata aaggaatcgg taggaaaaca 
1861  tctacctcag attcctccct tggaaaaaat gagaagtcct ggctttttga atattctaca 
1921  aaatcaggct accaacaaat tcataatagt aaaaagactc gtgtcactgt gtcctccact 
1981  ggctttaaac ttttaggagt gtatctggac tggcctgctg gcactctgtc cttctacatg 
2041  gtcaacaaag cctgggttac tcatctccac actttccaca ccaaatttaa tgaagctgtt 
2101  tatccagcct tcttgattgg ggatgcacaa cagaaagtca atggtcaaat taaattattg 
2161  taaaatgttt gtgcaccaaa tccagactct ttagcagtac atgtagttgg ttcctcagag 
2221  ttagtggaat aattacacaa caataataat aataattata ataattacag gaagttgatg 
2281  ccaatatatg cttaaaaaaa taaatggcat caatattgtc aagaatccat ttggaattgt 
2341  gggggtttcc tattttgggt ggcagtagca gtaatagtag taatagtagt agtagtagta 
2401  atcagagatc ctactacaag tgtgttttaa tataaattta tacgcaataa atgatacgtt 
2461  aaaataagat aatgttggat acagtaaaaa gattcaaaat gcagagaaac attatgagtt 
2521  actgtggaaa cagctttaaa tgttacatgg aagttacaaa ttgcaattaa aaaaaagcat 
2581  gtaataggaa tataattaaa catttgggga acttgctatc ttgatttctt gcagtgttac 
2641  tttaatgaca agtatcgtgt ttttacattg ctattattgt cctattagtt tttacatcag 
2701  tgcacaataa gccgcaacaa tcaacaacag attctagtat  
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1.2.6.3 AMINO ACID SEQUENCE ALIGNMENT  
 
Amino acid sequence alignment using BLAST indicates that the SNTX subunits 
exhibit 47% homology to each other. More sequence alignments with BLAST 
showed that SNTX-β exhibits 90% homology to both verrucotoxin-α and 
verrucotoxin-β subunits that make up Verrucotoxin. Verrucotoxin, a lethal 
hypotensive and cytolytic factor from stonefish S. Verrucosa is made up of 4 
subunits, 2 α subunits (83kDa) and 2 β subunits (78kDa) (Garnier et al., 1995).  
 
SNTX-α in contrast, exhibited only 46% homology to the verrucotoxin alpha and 
beta subunits. SNTX like verrucotoxin, show no significant homology to other 
proteins except that they possess a small stretch of amino acids that make up a B30.2 
domain.  
 




SNTX shows no significant homology to other proteins except that it possess a small 
stretch of amino acids that make up a B30.2 domain that is present in many proteins 
of diverse functions and cellular locations (Henry et al., 1998). These proteins include 
the human 52 kDa Sjogren's syndrome nuclear antigen A/Ro (SSA/Ro), the ret finger 
protein (rfp), Xenopus nuclear factor 7 (xnf7), bovine butyrophilin (BTN), etc. This 
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huge family of B30.2 domain-containing proteins is classified by Henry et al. (1998) 
and Seto et al. (1999) according to the type of N-terminal domain found in each 
protein (Figure 7).  
 
The first category of B30.2 domain-containing proteins comprises a subset of RING 
finger proteins with Bbox and coiled-coil domains, and includes rfp, SSA/Ro, acid 
fingerprotein (AFP), RING finger B30 protein (RFB30) and transcription regulator 
Staf-50 protein (Staf50). Two other members of this family contain an additional N-
terminal region with an acidic character, xnf7 and Pleurodeles waltl (PwA33). Other   
 
Figure 7. The B30.2-domain containing family of proteins. (Diagram adapted from 
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family members comprise variations of this canonical structure. In pyrin, the N-
terminal domain is unique, and there is no RING motif, and the B30.2 domain is 
truncated, while the estrogen finger protein (efp) has two Bbox motifs. Currently, this 
category of B30.2 domain containing proteins are found to be involved in the 
regulation of cell growth and differentiation (Inoue et al., 1993; Reddy et al., 1991; 
Tissot et al., 1995; Bellini et al., 1993; Itoh et al., 1991; Takahashi et al., 1988). Their 
subcellular localization has also been shown to be both nuclear and cytoplasmic (Liu 
et al., 1998; El-Hodiri et al., 1997; Miyagawa et al., 1998). 
 
The second type of N-terminal region associated with B30.2-like domains comprises 
two extracellular immunoglobulin-like domains, IgV and IgC, and is present in a 
family of butyrophilin-related proteins (Henry et al., 1997; Taylor et al., 1996). The 
B30.2 domain of BTN, shown to be associated with xanthine dehydrogenase/oxidase, 
has been suggested to function in a complex with other proteins in the budding and 
release of milk-fat globules from the apical membrane during lactation (Ishii et al., 
1995; Banghart et al., 1998). Although BTN is a transmembrane protein, the B30.2-
like domain of BTN is cytoplasmic. 
 
The third family of B30.2 domain-containing proteins consists of SNTX-α and 
SNTX-β, two subunits within SNTX that is secreted possibly via the non-classical 
pathway (Ghadessey et al., 1994 & 1996). SNTX possess various biological activities 
that include potent species-specific hemolysis (Duhig & Jones, 1928; Poh et al., 
1991), platelet aggragation (Khoo et al., 1995), oedema induction (Poh et al., 1991), 
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endothelium-dependent vasorelaxation (Low et al., 1993), hypotension (Low et al., 
1993), inhibition of neuromuscular junction (Low et al., 1994) and lethality (Poh et 
al., 1991; Low et al., 1993).  
 
1.2.6.4.2 CLONING AND EXPRESSION 
 
The B30.2 domain in SNTX-α and SNTX-β have been amplified by PCR and cloned 
into various bacterial expression systems (Sung, 2001).  
 
In the first instance, the B30.2 domains of SNTX-α and SNTX-β were expressed as 
fusion proteins with 6X His tag using the pQE QIAexpress System. pQE30 vector 
and E. coli M15 host cells were used. The cultures were induced in late logarithmic 
phase at 30°C by 0.1 to 1mM IPTG for four hours and SDS-PAGE showed that the 
His-αB30.2 and His-βB30.2 recombinant proteins were highly expressed within the 
inclusion bodies. In the presence of 0.1mM IPTG at 30°C, the expression of the major 
part of the recombinant proteins as inclusion bodies increased with time from 1-4 
hours. Very little recombinant protein was expressed as soluble fractions in the 
supernatant. An attempt at purifying recombinant His-αB30.2 under native conditions 
from the soluble fraction resulted in no significant yield of pure protein. Under 
denaturing conditions, there was a significant yield of His-αB30.2. However 
according to the author, attempts made to refold His-αB30.2 using slow dialysis 
against decreasing concentration of urea or direct dilution with 1X PBS was not 
successful.  
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Sung (2001) also tried expressing the B30.2 domains of SNTX-α and SNTX-β as 
fusion proteins using the pET system. pET-22b(+)  vector and E. coli BL21(DE3) 
host cells were used. pET-22b(+) has a signal sequence that directs expressed 
heterologous proteins to the periplasm, a common strategy employed when 
attempting to isolate active and folded proteins. However, both the expressed 
pET22b(+)-αB30.2 and pET22b(+)-βB30.2 fusion proteins were found as inclusion 
bodies in the cytoplasmic fraction instead, presumably due to the incompetent nature 
of the protein to localize to the periplasm. The recombinant proteins were expressed 
in majority as insoluble inclusion bodies at a temperature of 37°C with different IPTG 
concentration for 4hrs.  
 
Lastly, the pGEX system was employed to try to increase the solubility of the cloned 
B30.2 domains of SNTX-α and SNTX-β by utilizing the hydrophilic nature of the 
GST affinity tag. pGEX-5X-1 vector and E. coli BL21(DE3) host cells were used 
(Sung, 2001). Bacterial cultures were grown at 30°C until OD600 = 0.5 before being 
induced with different concentrations of IPTG for 4hrs. GST-αB30.2 and GST-
βB30.2 were found to be expressed both in the soluble fraction and as inclusion 
bodies, with no conclusive evidence showing the preferential distribution of the 
fusion proteins. Using the soluble fractions, purification attempts with glutathione-
agarose columns resulted in the co-purification of GroEL with both GST-αB30.2 and 
GST-βB30.2. To remove co-purifying Gro-EL, an ATP washing step was applied 
while the GST fusion proteins remained attached to the affinity column. GST-βB30.2 
but not GST-αB30.2 was efficiently removed from GroEL. As a further attempt to 
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remove GroEL from GST-αB30.2, an ATP-GroES washing step was used but pure 
GST-αB30.2 cannot be obtained. The amount of GST-αB30.2 (copurified with 
GroEL) and pure GST-βB30.2 obtained after purification inclusive of an ATP wash 
were approximately 340µg/l and 230µg/l respectively. 
 
1.2.6.5 SPECIES-SPECIFIC HAEMOLYTIC ACTIVITY: PORE 
FORMATION AND THE ROLE OF CATIONIC AMINO ACID RESIDUES 
 
SNTX causes species-specific haemolytic activity (Duhig & Jones, 1928; Poh et al., 
1991). It lyses washed erythrocytes and diluted blood of rat, guinea-pig and rabbit, 
but not rabbit or human red blood cells. Haemolysis was postulated to be due to a 
pore-forming mechanism by SNTX and cationic residues in SNTX may play a crucial 
role (Chen et al., 1997).  
 
SNTX-induced haemolysis was completely prevented by osmotic protectants of 
adequate size [poly(ethylene) glycol 3000: molecular diameter approx. 3.2nm]. 
Uncharged molecules of smaller size, such as raffinose and poly(ethylene) glycol 
1000-2000, failed to protect against cell lysis. In addition, SNTX lost its haemolytic 
activity when the positively charged side chains of lysine residues were neutralized or 
converted into negatively charged side chains upon carbamylation or succinylation 
respectively. The haemolytic activity of SNTX was also inhibited by the modification 
of positively charged arginine residues using 2, 3-butanedione. The loss of 
haemolysis showed strong correlation with the number of Lys or Arg residues 
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modified. CD analysis, however, showed that the conformation of SNTX was not 
severely affected by these chemical modifications. Further, the haemolytic activity of 
SNTX was competitively inhibited by various negatively charged lipids, such as 
phosphatidylserine, cardiolipin and monosialogangliosides. Neutral or zwitterionic 
lipids such as phophatidylcholine, phosphatidylethanolamine, sphingomyelin and 
cholesterol did not affect the hemolytic activity of SNTX.  
 
1.2.6.6 EFFECTS ON PLATELET AGGREGATION 
 
SNTX induces platelet aggregation in whole blood which correlates with its effects 
on species-restricted haemolysis (Khoo et al., 1995). SNTX induced a concentration-
dependent and irreversible platelet aggregation in rabbit or rat but not in human or 
mouse whole blood. Although SNTX itself could not induce platelet aggregation in 
rabbit or rat platelet-rich plasma (PRP), it had biphasic effects on collagen- or ADP-
induced platelet aggregation in PRP. It inhibited collagen- or ADP-induced platelet 
aggregation at high concentrations (0.08-0.8µg/ml) but the response was potentiated 
by lower stonustoxin concentrations (0.008-0.016µg/ml).  
 
The inhibition of collagen- or ADP-induced platelet aggregation might be due to the 
lytic activity of SNTX on the platelets. However, lysis of platelets caused by SNTX 
did not appear to affect platelet aggregation observed in whole blood. A possible 
reason postulated is that the ratio of the concentration of platelets to erythrocytes is 
about 1 to 28 in rabbit blood and so when added to whole blood, SNTX would have a 
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higher probability of lysing the RBCs instead of the platelets although the ED50 of 
SNTX is approximately 0.06µg/109 RBC for haemolysis and 0.038µg/107 platelets 
for platelet lysis. The number of lysed platelets would therefore be relatively low and 
therefore enough platelets would still be available for aggregation to proceed.  
 
Low concentrations of SNTX potentiated collagen-induced platelet aggregation in 
rabbit PRP. At these concentrations, platelet lysis was undetectable. The potentiation 
was not inhibited by apyrase which is an ADP scavenger. Thus the potentiation did 
not appear to be mediated by ADP released from the platelets. Further work should be 
done to elucidate the underlying mechanism(s) by which SNTX potentiates platelet 
aggregation, such as activating the cyclooxygenase pathway, mobilizing Ca2+ from 
intracellular stores, decreasing cAMP levels or activating endogenous phospholipase 
A2. 
 
1.2.6.7 EDEMA-INDUCING ACTIVITY 
 
SNTX exhibits potent edema-inducing activity (Poh et al., 1991). The minimum 
edema dose (MED) is 0.15 µg in mouse paw and maximum swelling occurs within 60 
min of SNTX injection. The edema inducing effect was not inhibited by 
diphenhydramine, suggesting that histamine release did not mediate the increase in 
vascular permeability. Such venom-induced modifications of vascular permeability 
may account for the potent hypotension associated with S. horrida envenomation.  
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SNTX (5-20µg/kg) produced dose-dependent falls in blood pressure in anaesthetized 
rats (Low et al., 1993). At the highest dose used, there was no recovery from the 
marked fall in blood pressure and cessation of respiration occurred. SNTX at these 
doses used, caused no significant effects on the twitch responses of the tibialis and 
diaphragm muscles to stimulation by the sciatic and phrenic nerve respectively.  
 
1.2.6.8.2 VASORELAXATION OF PRECONTRACTED RAT AORTA 
 
1.2.6.8.2.1 STUDIES BY LOW et al., 1993 – ENDOTHELIUM-DEPENDENCE 
& INVOLVEMENT OF L-ARGININE-NITRIC OXIDE SYNTHASE 
PATHWAY, A DETAILED RELOOK 
 
SNTX (20-160ng/ml) causes an endothelium-dependent vasorelaxant effect on rat’s 
aortic strips pre-contracted with 25nM noradrenaline (NA). The relaxation was fairly 
well-sustained and lasted between 10-20min. The aortic strips used were shown 
before actual experimentation to possess an intact endothelium: when precontracted 
with 25nM NA, they further respond to 0.8mM acetylcholine (Ach) with nearly 
complete relaxation (82.2 ± 7.9%). Higher concentrations of SNTX (> 0.4µg/ml) 
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caused rapid, transient relaxations that were quickly followed by an increase in tone 
of these endothelium-intact, NA-precontracted aortic strips.  
 
In NA-precontracted aortic strips with endothelium removed, no relaxation to 0.8mM 
Ach or to SNTX at concentrations up to 160ng/ml was observed. SNTX (> 0.4µg/ml) 
added to these precontracted strips denuded of endothelium caused a rapid increase in 
tone without producing any relaxant effect. It was also observed that SNTX at 
concentrations up to 400ng/ml did not affect the resting tension of intact or 
endothelium-denuded aortic strips.  
 
Preincubation of endothelium-intact aortic strips with 25µM L-NG-nitro arginine 
methyl ester (L-NAME), 10µM methylene blue or 5mM hemoglobin for 25min 
completely abolished the relaxations induced by 20-160ng/ml SNTX on 25nM NA-
precontracted aortic strips. L-NAME is a specific and competitive nitric oxide 
synthase (NOS) inhibitor while methylene blue inhibits guanylate cyclase activation 
(Gruetter et al., 1981; Rapoport and Murad, 1983). On the other hand, hemoglobin 
binds nitric oxide (NO) (Martin et al., 1985; Ignarro et al., 1987). These inhibitions of 
SNTX’s effects were not reversed by flushing L-NAME out of the organ bath with 
fresh Krebs but were reversed by flushing away methylene blue and hemoglobin. In 
addition, upon addition of 25nM NA to aortic strips preincubated with 25µM L-
NAME or 10µM methylene blue, there was an approximately 2-fold and 1.3-fold 
increase in the contraction of the intact aortic strip in response to 25nM NA 
respectively. In addition, incubation of intact aortic strips with 75µM L-arginine led 
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to the reversal of the inhibitory effect of L-NAME on SNTX’s effect. From these, it 
was concluded that SNTX possibly mediates its relaxant activity via the L-arginine-
nitric oxide synthase pathway. 
 
1.2.6.8.2.2 STUDIES BY SUNG et al., 2002 – INVOLVEMENT OF 
SUBSTANCE P RECEPTORS, INDUCIBLE NITRIC OXIDE SYNTHASE 
AND POTASSIUM CHANNELS 
 
Sung et al. (2002) further characterized the mechanisms that are responsible for 
SNTX-mediated vasorelaxation of 75.2µM L-phenylephrine (PE) precontracted, 
endothelium-intact rat’s thoracic aortic rings that are 4mm in length. Endothelium-
intact aortic rings in their work refer to 75µM PE-precontracted aortic rings that 
respond to 2µM Ach with greater or equal 70% vasorelaxation. PE used in these 
experiments like NA used by Low et al. (1993), produces vasoconstriction of vascular 
smooth muscle by binding to alpha adrenoceptors (Katzung, 1998). However, PE 
unlike NA is not a catechol derivative that is inactivated by Catechol-O-
methyltransferase (COMT).  Hence PE produces a more easily monitored stable 
contractile response of the aorta than NA. The vasorelaxant effect produced by SNTX 
on PE-precontracted aortic rings should theoretically show less variation than NA-
precontracted aortic rings. 
  
Sung et al. (2002) showed that progressive addition of SNTX to 75.2µM PE-
precontracted endothelium intact aortic rings results in a cumulative dose-relaxant 
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effect. The SNTX cumulative dose-response curve has an IC50 of 132.7ng/ml and a 
maximum vasorelaxation of 72.7 ± 6%. She also showed that preincubation of the 
aortic rings for 30min with 0.5mM 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine 
(AMT-HCl) or 0.5mM N-acetyl-L-tryptophan-3,5-bis(trifluromethyl)-benzyl ester 
(NATB) completely abolished the vasorelaxant effect of SNTX. AMT-HCl is a 
specific inducible nitric oxide synthase (iNOS) inhibitor (Nakane et al., 1995), while 
NATB is a substance P (SP) receptor antagonist.  In addition, preincubation of the 
aortic rings for 30 min with 3mM tetraethylammonium (TEA) led to the partial 
inhibition of SNTX’s effect with maximum vasorelaxation decreased to 25.4 ± 8%. 
TEA is a non-selective K+-channel inhibitor (Armstrong, 1971). 
 
Combining the results by Low et al. (1993), Julia et al. (2002) postulated that a 
component of SNTX-mediated vasorelaxation in precontracted rat aortic rings is via 
binding of either SNTX or SP to the SP receptors that are located on the endothelial 
cells (Figure 8). Occupation of these SP receptors causes the subsequent activation of 
nitric oxide synthase (NOS) and the production of NO that diffuses into vascular 
smooth muscle to affect an increase in the levels of cyclic guanylyl monophosphate 
(cGMP) via the activation of guanylyl cyclase. cGMP then activates K+-channels, 
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Figure 8. Postulated components of SNTX-mediated vasorelaxation in the 
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1.2.6.9 NEUROMUSCULAR EFFECTS 
 
SNTX (8-50µg/ml) produced a rapid and concentration-dependent rise in tension 
(contracture) of  electrically-stimulated mouse hemidiaphragm followed by a gradual 
waning of tension from the peak to the baseline; the nerve-evoked and the directly 
(muscle)-evoked twitches of the hemidiaphragm were also progressively and 
irreversibly blocked in a time- and concentration-dependent manner (Low et al., 
1994). The muscle contracture produced by SNTX was blocked by dantrolene sodium 
(6µM) but not by tubocurarine (15µM). SNTX (22 and 44µg/ml) produced a similar 
rapid rise in tension of the chick biventer cervicis muscle (CBCM) as well as 
irreversible and concentration dependent blockade of nerve-evoked twitches and 
contractures produced by acetylcholine (200µM), carbochol (8µM) and KCl (40mM). 
In addition, SNTX (40µg/ml) did not inhibit any nerve conduction in the toad sciatic 
nerve and SNTX (60µg/ml) did not exhibit any anticholinesterase activity.  
 
SNTX produced marked and concentration-dependent contractures of the mouse 
hemidiaphragm in the presence of 15µM tubocurarine which indicated that SNTX can 
act directly on the muscle to produce a contractile response and ruled out the 
involvement of a prejunctional mechanism in the mediation of the contractures which 
also could not be attributed to any anticholinesterase activity of SNTX since this was 
found to be absent in the toxin. The marked blockade by dantrolene sodium of the 
SNTX-induced contractures of the mouse hemidiaphragm indicates that SNTX could 
not have acted directly on the contractile muscle proteins to produce the contractures, 
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since dantrolene mediates its blocking action primarily by inhibiting the release of 
calcium from the sarcoplasmic reticulum, i.e. prior to activation of the contractile 
proteins (Hainut and Desmedt, 1984). SNTX-induced contracture may be the result of 
SNTX causing direct muscular depolarization, since the crude venom of S. trachynis 
has been shown to produce extensive depolarization of skeletal muscle fibres of the 
rat (Kreger et al., 1993). 
 
Blockade of indirectly evoked twitches by SNTX is not likely to be due to nerve 
conduction block since, at the concentrations used, SNTX did not affect action 
potentials in the toad sciatic nerve. The ability of SNTX to block directly evoked 
twitches indicates that SNTX acts directly on the muscle to inhibit neuromuscular 
function. The complete blockade of the contractile responses of the CBCM to Ach 
and CCh, as well as to KCl, also provides strong evidence that the inhibitory action of 
SNTX on neuromuscular function may be attributed to some direct effects of SNTX 
on the muscle. Since SNTX produced irreversible blockade of directly and indirectly 
evoked twitches of the skeletal muscle preparations used, it is likely that SNTX 
induced some permanent damage to the neuromuscular apparatus in skeletal muscle. 
It has recently been reported that large concentrations (100-300µg/ml) of the crude 
venom of S. trachynis produced muscle and nerve damage visible under the electron 
microscope; it was reported also that the crude venom of S. trachynis can cause 
depletion of neurotransmitter as a consequence of massive transmitter release as well 
as block of synaptic vesicle recycling (Kreger et al., 1993), prejunctional actions 
which also contribute to the neuromuscular function in skeletal muscle. 
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1.2.6.10 DEVELOPMENT OF MONOCLONAL ANTIBODIES 
 
Eight monoclonal antibodies have been developed by Yuen et al. (1995) using the 
Balb/C mouse, and purified by Protein G affinity membrane disc chromatography. 
These MAbs are designated as MAbs 8A, 31A, 32B, 38A, 43B, 43D, 44G, 46A 
respectively. Four of the Mabs were found to have similar epitope specificity while 
the rest were directed at different epitopes on the SNTX molecule. Although six of 
these monospecific antibodies were able to protect mice from a challenge of a lethal 
dose of SNTX, not all the protective MAbs were able to neutralize the hemolytic 
effect of SNTX in vitro; which suggests the domain(s) responsible for both biological 
activity may be different. 
 
1.2.6.11 CRYSTALLIZATION AND PRELIMINARY CRYSTALLOGRAPHIC 
STUDY  
 
Crystals of SNTX have been obtained and diffract to a 3.4 Å resolution (Yew et al., 
1999). The crystals belong to the tetragonal space group P422, with unit cell 
constants a = b = 109.0 Å, c = 245.7 Å. A native SNTX has two subunits, designated 
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1.2.6.12 CHEMICAL MODIFICATIONS 
 
Chemical modifications of proteins in solution can provide important structural and 
functional information. In many ways, chemical modification is complementary to 
site-directed mutagenesis as a methodology for the study of protein variants. 
Although the latter method is favorable because the importance of specific amino acid 
residues can be determined, chemical modification is still useful when biologically 
active recombinant proteins of interest is not available for site-directed mutagenesis 
studies. SNTX have been characterized by chemical modification and several amino 
acids such as cationic lysine and arginine residues, free thiol and tryptophan have 
been found to play important roles in its various biological activities including 
lethality and haemolysis (Yew et al., 2000; Khoo et al., 1998a; Khoo et al., 1998b; 
Chen et al., 1997).   
 
1.2.7 HYALURONIDASE – A SECOND PROTEIN ISOLATED FROM S. 
HORRIDA VENOM  
 
Hyaluronidase was purified from S. horrida venom via a Sephacryl S-200 High 
Resolution (HR) gel filtration chromatography, followed by a Heparin Agarose 
affinity chromatography (Poh et al., 1992). The first process involved resolving the 
venom into five fractions, of which fraction 2 exhibited hyaluronidase activity. This 
fraction was then subjected to affinity chromatography which yielded four fractions 
of which fraction 4 contained hyaluronidase. This fraction gave only a single band in 
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a 10% SDS-PAGE gel. The purified hyaluronidase has a molecular weight of 62 kDa, 
as obtained by SDS-PAGE and Sephadex G-100. It has a pI of 9.2, is heat sensitive 
and is inhibited by Cu2+, Hg2+ and heparin. It does not contain hemorrhagic or lethal 
activity. Its N-terminal sequence has also been determined to be A-P-S-X-D-E-G-N-
K-K-A-D-N-L-L-V-K-K-I-N. 
 
The reaction products of the hyaluronidase purified from stonefish venom consists of 
tetra-, hexa-, octa- and deca-saccharides as major end products, but not disaccharides 
(Sugahara et al., 1992). The structure of the tetrasaccharide product was determined 
by enzymic analysis, in conjuction with HPLC and H-NMR, as GlcAβ1-3GlcNAcβ1-
4GlcAβ1-3GlcNAc. Chemical shifts of the structural-reporter-group protons of the 
constituent monosaccharides for the tetrasaccharide have been assigned. The enzyme 
did not act on chondroitin sulphate or dermatan sulphate. The results indicate that 
stonefish hyaluronidase is an endo-β-N-acetylglucosaminidase specific for 
hyaluronate. 
 
1.2.8 OTHER SYNANCEJA SPECIES 
 
1.2.8.1 SYNANCEJA TRACHYNIS  
 
Trachynilysin (TLY), a dimeric protein purified from S. trachynis venom has a 
molecular weight of 158kDa and a pI of 5.7 (Kreger, 1991). It contains the venom’s 
haemolytic, as well as the lethal and vascular permeability increasing activity 
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(Kreger, 1991). TLY forms pores in planar lipid bilayers (Mattei et al., 2000) and 
mediates soluble N-ethylmaleimide-sensitive fusion protein attachment protein 
receptor (SNARE)-dependent release of catecholamines from chromaffin cells via 
external and stored Ca2+ (Meunier et al., 2000) It increases spontaneous quantal 
acetylcholine release from neuromuscular junctions (Ouanounou et al., 2000). It also 
enhanced the release of Ach from atrial cholinergic nerve terminals and indirectly 
activated muscarinic receptors (Sauviat et al., 2000). It was also shown that TLY 
selectively stimulated the release of small, clear synaptic vesicles and impaired the 
recycling of small, clear synaptic vesicles but did not affect the release of large dense-
core vesicles (Colasante et al., 1996). 
 
1.2.8.2 SYNANCEJA VERRUCOSA  
 
Unlike SNTX and TLY, verrucotoxin (VTX) purified from S. verrucosa venom was 
found to be a glycoprotein with a high molecular weight of 322kDa, comprising four 
subunits, 2 α- (83 000) and 2 β- (78 000) (Garnier et al., 1995). Just like the crude 
venom, VTX was lethal in mice, lysed washed rabbit erythrocytes and induced a fall 
in blood pressure (Garnier et al., 1995). VTX was found to inhibit calcium channels 
and may activate ATP-sensitive K+ channels in frog atrial heart muscle (Garnier et 
al., 1997). In addition to TLY, S. verrucosa venom also contained noradrenaline and 
other biogenic amines, such as dopamine and tryptophan, but not 5-
hydroxytryptamine (Garnier et al., 1996). Numerous enzymatic activities, i.e. 
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hyaluronidase, esterase and aminopeptidase are also present in the crude venom 
(Garnier et al., 1995). 
 




Hydrogen sulfide (H2S) is commonly known as “Sewer Gas”. It is a colorless, 
flammable gas with a strong odor of rotten eggs. It occurs naturally in crude 
petroleum, natural gas, volcanic gases, hot springs and is produced from the bacterial 
breakdown of organic matter, human and animal wastes (US Environmental 
Protection Agency - Public health statement for H2S, 1999). It is produced from 
industrial activities such as food processing, coke ovens, kraft paper mills, tanneries 
and petroleum refineries. Throughout the years, hydrogen sulfide has been associated 
with many industrial fatalities (Burnett et al., 1977; Guidotti, 1994; Synder et al., 
1995). The detectable level of this gas by the human nose is at a concentration 400-
fold lower than the toxic level and desensitization of the olfactory system can occur 
within minutes. Symptoms associated with H2S exposure include eye irritation, sore 
throat, cough, shortness of breath and fluid in the lungs upon low levels of exposure 
to the gas. Upon long-term exposure, H2S causes fatigue, loss of appetite, headaches, 
irritability, poor memory and dizziness. At high levels of exposure to the gas, there 
can be loss of consciousness and death can occur.  
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Despite the toxicity associated with H2S, it has been found to be produced 
endogenously in mammalian cells during L-cyst(e)ine metabolism (Stipanuk & Beck, 
1982). In rat serum, circulating H2S concentration is ~ 46µM (Zhao et al., 2001). 
Relatively high levels of H2S (50-160µM) have also been measured in brains of rats, 
humans and bovine (Goodwin et al., 1989; Warenycia et al., 1989; Savage and 
Gould, 1990). Rat ileum as well as different vascular tissues such as rat thoracic aorta 
and portal vein also generate measurable amounts of H2S (Zhao et al., 2001; Hosoki 
et al., 1997). In addition, H2S-generating enzymes have also been detected in liver, 
kidney and heart (Stipanuk and Beck, 1982; De La Rosa et al., 1987; Nagahara et al., 
1998). Currently, the physiological roles of this novel H2S biological gas are being 
explored. 
 
1.3.2 ENDOGENOUS GENERATION OF H2S: DESULFHYDRATION OF L-
CYST(E)INE 
 
The synthesis of H2S occurs during the desulfhydration of L-cyst(e)ine. L-cysteine is 
a semi-essential amino acid that can be synthesized from methionine and serine via a 
unidirectional transulfuration pathway. Methionine is an essential amino acid and like 
L-cysteine, is normally consumed as components of dietary proteins. The biochemical 
pathways leading to H2S production in mammalian mitochondria and cytosol involves 
several enzymes (Stipanuk & Beck, 1982; Stipanuk, 2004; Kamoun, 2004). Some of 
these enzymes are produced both in mitochondria and in the cytosol i.e. cysteine 
aminotransferase and 3-mercaptosulfurtransferase (MSPT; 2.8.1.2) whereas others i.e. 
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cystathionine-γ-lyase (CSE; EC 4.4.1.1) and cystathionine-β-synthase (CBS; EC 
4.2.1.22) are only produced in the cytosol. Cytosolic and mitochondrial cysteine 
aminotransferase are identical to cytosolic (Akagi, 1982) and mitochondrial (Ubuka 
et al., 1978) aspartate aminotransferase, respectively (EC 2.6.1.1 and EC 2.6.1.3, 
respectively). The expression of H2S-generating enzymes depends on the species and 
organ involved. Generally, the pathways leading to H2S production in mammalian 
tissues elucidated to-date using liver and kidney tissues are depicted in Figures 9 and 
10. 
 
One pathway of L-cysteine metabolism involves its oxidation to cysteinesulfinate. 
Cysteinesulfinate is then either decarboxylated in cytosol to yield hypotaurine which 
is further oxidized to taurine (Figure 9) or transaminated in mitochondria to yield 
pyruvate and sulfite (Stipanuk, 1986) (Figure 10). The sulfite produced is readily 
oxidized to sulfate.  L-cyst(e)ine is also metaboilized via cysteinesulfinate-
independent pathways (Coloso & Stipanuk, 1989). Cystathionine-γ-lyase, a pyridoxal 
5’-phosphate-dependent enzyme, catalyzes a β-disulfide elimination reaction that 
cleaves the sulfur from L-cyst(e)ine, resulting in the production of pyruvate, NH4+ 
and thiocysteine (Figure 9). Thiocysteine may react with L-cysteine or other thiols to 
form H2S (Stipanuk and Beck, 1982; Yamanashi and Tuboi, 1981). Cystathionine-β-
synthase, another pyridoxal 5’-phosphate-dependent heme protein can synthesize H2S 
from L-cysteine (Stipanuk and Beck, 1982; Griffith, 1987; Swaroop et al., 1992) 
(Figure 9). H2S is formed by the substitution of the thiol group of L-cysteine with a 
variety of thiol compounds to form the corresponding thioether. Another pathway 
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leading to H2S generation involves transamination of L-cysteine by aminotransferases 
to yield 3-mercaptopyruvate which is further catabolised by 3-mercaptopyruvate 
sulfurtransferase (Stipanuk and Beck, 1982; Stipanuk, 1986) (Figure 9 and 10). 
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1.3.3 CATABOLISM OF H2S 
 
The pathways by which hydrogen sulfide is converted to sulfate in mammalian tissues 
(Figures 9 and 10) have been explored mainly using liver and kidney tissues 
(Bartholomew et al., 1980; Ubuka et al., 1990, 1992; Huang et al., 1998). The 
oxidation of hydrogen sulfide to thiosulfate is catalyzed by heme compounds (Sorbo, 
1958), metal-protein complexes and ferritin (Ubuka et al., 1992). One molecule of 
thiosulfate is formed from two molecules of hydrogen sulfide. Two enzymes 
thiosulfate sulfurtransferase and thiosulfate reductase then act on thiosulfate 
(Westley, 1980). Thiosulfate reductase catalyzes the reaction of thiosulfate with 
reduced glutathione. Oxidized glutathione is reduced by mitochondrial glutathione 
reductase. Thiosulfate sulfurtransferase, in comparison, was found to be poorly 
efficient in the catabolism of thiosulfate (Huang et al., 1998). Sulfite oxidase (EC 
1.8.2.1) a soluble protein found in the intermembrane space of mitochondria (Cohen 
et al., 1972) has ready access to its reducing substrate, sulfite, which can diffuse 
across mitochondrial membranes, and to its physiological acceptor, cytochrome c. 
Sulfite oxidase, a molybdenum containing enzyme, forms sulfate from sulfite. In 
mammals, H2S is excreted mainly by the kidney as free or conjugated sulfate 
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1.3.4 H2S & THE CARDIOVASCULAR SYSTEM 
 
1.3.4.1 EXPRESSION OF H2S-GENERATING ENZYMES 
 
In vascular tissues, CSE is the only H2S-generating enzyme that has been identified 
to-date (Hosoki et al., 1997; Zhao et al., 2001). CSE in rat mesenteric artery (Pubmed 
ID: AB052882) and other vascular tissues (Pubmed ID: AY032872) has been cloned 
and sequenced (Zhao et al., 2001). mRNA of this enzyme was expressed solely in 
vascular smooth muscle cells as detected by RT-PCR and in situ hybridization (Zhao 
et al., 2001). No transcript of CSE was found in the endothelium layers of intact 
vascular tissues or cultured endothelial cells (Zhao et al., 2001). Expression levels of 
CSE mRNA varied in different types of vascular tissues, with an intensity rank of 
pulmonary artery > aorta > tail artery > mesenteric artery (Zhao et al., 2001). The 
expression of CSE (43kDa) at protein level has also been demonstrated in rat aorta, 
mesenteric artery smooth muscle, tail artery smooth muscle and pulmonary artery 
smooth muscle (Cheng et al., 2004). The expression level of CSE protein was similar 
in the different vascular tissues. 
 
In contrast, no/little expression of cystathionine-β-synthase (CBS) has been found in 
human atrium, ventricle tissues, internal mammary arteries, saphenous veins, 
coronary arteries, or aortic arteries (Chen et al., 1999; Bao et al., 1998). As such, 
CBS does not appear to play a major role in generating H2S in cardiovascular tissues 
under physiological conditions. 
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1.3.4.2 PHYSIOLOGICAL EFFECTS OF H2S 
 
1.3.4.2.1 IN VIVO: DECREASE IN BLOOD PRESSURE 
An intravenous bolus injection of H2S at 2.8 and 14µmol/kg body weight transiently 
decreased blood pressure of rats by ~ 12 and 30 mmHg respectively, an effect 
mimicked by pinacidil (a KATP channel opener) and antagonized by glibenclamide (a 
KATP channel blocker) (Zhao et al., 2001).  
 
1.3.4.2.2 IN VITRO: VASORELAXATION 
 
1.3.4.2.2.1 ROLE OF ENDOTHELIUM & ENDOTHELIUM-DERIVED 
RELAXING FACTOR (EDRF) 
 
H2S induced in vitro dose-dependent relaxation of rat precontracted aorta, portal vein 
and mesenteric artery beds (MAB), as well as electrically stimulated vas deferens 
(Hosoki et al., 1997; Zhao and Wang, 2002; Wang, 2002; Teague et al., 2002; Cheng 
et al., 2004). The H2S-induced vasorelaxation of precontracted rat aorta was not 
affected significantly by vascular denervation, suggesting that the vasorelaxant effect 
of H2S is not due to the altered neurotransmitter release from the autonomous or 
NANC nerve endings (Zhao and Wang, 2002). H2S-induced relaxation of 
precontracted aorta and MAB was assessed after endothelium-removal, application of 
L-NAME or coapplication of apamin and charybdotoxin, and the H2S concentration-
response curve was shifted to the right in all cases (P<0.05) (Zhao et al., 2001; Cheng 
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et al., 2004). In the presence of NO-donors such as Na-nitroprusside (SNP) and 
morpholinosydnonimine, H2S-induced vasorelaxation of precontracted thoracic aorta 
was greatly enhanced (Hosoki et al., 1997). These results suggest that H2S-induced 
vasorelaxation may be partially facilitated by an enodothelium-dependent mechanism 
involving the release of EDRF such as NO from the vascular endothelium. However, 
the NO-/endothelium-dependence of H2S-induced vasorelaxation is controversial as 
studies by Zhao and Wang (2002) showed that preincubation of aortic tissues with 60 
µM H2S for 15mins significantly inhibited SNP-induced vasorelaxation. 
 
1.3.4.2.2.2 INVOLVEMENT OF KATP CHANNELS 
 
It was postulated that H2S targets KATP channels in vascular SMCs to bring about 
vasorelaxation (Zhao et al., 2001; Cheng et al., 2004). H2S-induced relaxation of rat 
aortic tissues or mesenteric artery beds (MAB) precontracted with phenylephrine was 
mimicked by a KATP channel opener pinacidil but concentration-dependently inhibited 
by glibenclamide (Zhao et al., 2001; Cheng et al., 2004). In isolated single SMCs, 
KATP channel currents in rat aortic or MAB SMCs were significantly and reversibly 
increased by either H2S or pinacidil (Zhao et al., 2001; Cheng et al., 2004). Increased 
potassium conductance led to membrane hyperpolarization of SMCs that was 
reversible by gibenclamide (Zhao et al., 2001). A direct action of H2S on KATP 
channel proteins, rather than the interfered ATP metabolism by H2S, was proposed 
based on three lines of evidence (Zhao et al., 2001). First, intracellular ATP 
concentration in these studies was clamped at a fixed level by dialyzing cells with the 
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pipette solution. Second, the effect of H2S on KATP channels was quickly reversed on 
washing out H2S from the bath solution. Third, intentionally varying ATP 
concentrations inside the cell (from 0.2 to 3 mM) did not change the excitatory effect 
of H2S on KATP channels. The results by Zhao et al., 2001 identified H2S as the first 
gaseous opener of KATP channels in vascular SMCs.  
 
1.3.4.2.2.3 INDEPENDENCE OF cGMP PATHWAY 
 
Unlike NO or CO, H2S relaxation of vascular tissues was found to be independent of 
the activation of cGMP pathway (Zhao and Wang, 2002). Whereas the vasorelaxation 
induced by NO was virtually abolished by 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-
one (ODQ) or NS-2028, inhibitors of soluble guanylyl cyclase (sGC), the H2S-
induced vasorelaxation was potentiated by the inhibitors. The potentiated 
vasorelaxant effect of H2S by QDQ was suppressed by superoxide dismutase, 
suggesting that free radicals such as superoxides may be generated during QDQ-
potentiated H2S-induced vasorelaxation.  
 
1.3.4.3 ROLE OF H2S IN VASCULAR DISEASES 
 
Reduced expression and activity of CSE in lung tissues of hypoxic pulmonary 
hypertensive rats (Zhang et al., 2003) and in thoracic aorta of spontaneously 
hypertensive rats (Yan et al., 2003) was coupled with a decrease in plasma H2S 
concentration. In contrast, in septic and endotoxin shock rats, arterial H2S was 
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significantly increased (Yan et al., 2003). Exogenous supply of H2S could increase 
the plasma level of H2S, enhance CSE activity, oppose the rise in pulmonary arterial 
pressure as well as blood pressure, and lessen the pulmonary vascular and aorta 
structural remodeling that occurs during hypoxic pulmonary hypertension (HPH) and 
spontaneous hypertension respectively (Zhang et al., 2003; Yan et al., 2003). H2S 
may play a regulatory role in the pathogenesis of HPH through up-regulating the 
carbon monoxide/heme oxygenase pathway (Zhang et al., 2004). In addition, 
endogenous H2S/CSE pathway may be involved in the pathogenesis of isoproterenol-
induced myocardial injury (Geng et al., 2004). Administration of exogenous H2S 
effectively protects myocytes and contractile activity, at least by its direct scavenging 
of oxygen-free radicals and reducing the accumulation of lipid peroxidations (Geng et 
al., 2004). 
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1.4 AIMS OF STUDY 
 
 
Stonustoxin (Stonefish National University of Singapore, SNTX) is a 148kDa, 2-
subunit, multifunctional lethal factor isolated from Stonefish, Synanceja horrida 
venom (Poh et al., 1991). The myriad number of biological activities it cause include 
species-specific haemolysis and platelet aggregation, edema-induction, hypotension, 
endothelium-dependent vasorelaxation, and inhibition of neuromuscular function in 
the mouse hemidiaphragm and chick biventer cervicis muscle (Low et al., 1993; 
Khoo et al., 1995; Chen et al., 1997; Sung et al., 2002). In this thesis, the focus will 
be on delineating the biochemical pathways and the possible structural elements 
involved in the potent vasorelaxation caused by SNTX. Of interest is the potential 
involvement of hydrogen sulfide (H2S) acting in synergy with nitric oxide (NO) in 
SNTX-induced vasorelaxation. In addition, the role played by the SNTX B30.2 
domains in SNTX-induced vasorelaxation will also be investigated. 
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2.1 GENERAL MOLECULAR METHODS 
 
2.1.1 RNA AGAROSE/FORMALDEHYDE GEL ELECTROPHORESIS 
 
2.1.1.1 GEL PREPARATION 
 
Dissolve 1.0g agarose in 87ml H2O in microwave and cool to 60°C. Add 10ml 10X 
MOPS running buffer (0.4M MOPS, pH 7.0, 0.1M sodium acetate, 0.01m EDTA), 
3ml 12.3M (37%) formaldehyde, and 2µl ethidium bromide (10mg/ml). Pour the gel 
inside the fume hood and allow it to set. 
 
2.1.1.2 RNA SAMPLE PREPARATION AND ELECTROPHORESIS 
 
1. Prepare the total RNA sample as follow: 
RNA (0.5 – 10µg)   4.5µl 
10x MOPS running buffer 2.0µl 
12.3M formaldehyde  3.5µl 
Dionized formamide  10.0µl 
2. Incubate the sample at 65°C for 10mins and spin-down the sample. 
3. Add 2µl sterile RNA loading buffer (1mM EDTA, pH 8.0, 0.25% (w/v) 
bromophenol blue, 50% (v/v) glycerol) to the sample. 
4. Electrophoresis at 80V was carried out using 1x MOPS running buffer. 
5. After electrophoresis, wash the gel twice in deionized water. 
Chapter 2 Materials & Methods 
75 
2.1.1.3 QUANTITATION AND QUALITATIVE ANALYSIS OF TOTAL RNA  
 
Samples were diluted appropriately and OD260 and OD280 were measured using a 
quartz cuvette. 1 OD260 = 40 µg/ml RNA. OD260/OD280 should be between 1.5 and 2. 
 
2.1.2 DNA AGAROSE GEL ELECTROPHORESIS 
 
0.8% agarose gel in 1X TAE was prepared. After the molten agarose has cooled to 
~55°C, add ethidium bromide to a final concentration of 0.5µg/ml. Mix DNA with 
6X DNA gel loading buffer before gel loading.  
 
Composition of 6X DNA gel loading buffer: 0.09% bomophenol blue, 0.09% xylene 
cyanol FF, 60% glycerol and 60mM EDTA. 
 
2.1.2.1 PURIFICATION OF DNA CYCLE SEQUENCING PRODUCTS 
 
Ethanol Precipitation Protocol: 
1. For each reaction, prepare a 1.5ml microcentrifuge tube by adding 2µl of 3M 
sodium acetate, pH 4.6 and 50µl of 95% ethanol. 
2. Transfer the entire 20µl of cycle sequencing reaction product to the 
microcentrifuge tubes. Vortex and place on ice for 10mins. 
3. Centrifuge at 12,000X g for 20mins. 
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4. Remove the ethanol solution completely and rinse the pellet with 70% ethanol. 
Remove the ethanol and dry the pellet. 
 
2.1.3 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) 
 
Methods for denaturing (SDS) PAGE were adapted from Current Protocols in 
Molecular Biology (1999). Bio-Rad Mini-PROTEAN II gel set was used. 
 
2.1.3.1 SAMPLE PREPARATION 
 
For reducing SDS-PAGE, dissolve samples 1:5 with 6X PAGE loading buffer: 3.5M 
Tris-HCl, pH 6.8, 10.28% (w/v) SDS, 36% (v/v) glycerol, 5% mercaptoethanol, 
0.012% (w/v) bromophenol blue. Then, immediately heat the sample at 100°C for 5 
mins.  
 
For non-reducing SDS-PAGE, omit mercaptoethanol in the preparation of 6X PAGE 
loading buffer. 
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2.1.3.2 GEL PREPARATION 
 
Table 2. Receipe for denaturing polyacrylamide separating gels. 
Stock Solution Final acrylamide concentration in separating gel (%) 
  5 6 7 7.5 8 9 10 12 13 15
30% acrylamide / 0.8% bisacrylamide 1.67 2.00 2.33 2.50 2.67 3.00 3.33 4.00 4.33 5.00
1.5M Tris-C / 0.4% SDS; pH 8.8 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50
MilliQ water 5.83 5.50 5.17 5.00 4.83 4.50 4.17 3.50 3.17 2.50
10% (w/v) ammonium persulfate 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
TEMED 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
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Table 3. Receipe for denaturing polyacrylamide stacking gels. 
 
 
2.1.3.3 PROTEIN MARKERS 
 
For SDS-PAGE, Bio-Rad’s broad range molecular weight standard was used.  
 
2.1.3.4 RUNNING BUFFER 
 
The electrode buffer for SDS-PAGE is 0.025M Tris-HCl, pH 8.3 containing 0.192M 
glycine and 0.1% SDS.  
 
2.1.3.5 PAGE RUNNING CONDITION 
 
For one minigel, run at 15mA of constant current until the dye front reached the end 





Stock Solution Final acrylamide concentration (3.9%) 
30% acrylamide / 0.8% bisacrylamide 0.65
0.5M Tris-Cl / 0.4% SDS; Ph 6.8 1.25
MilliQ water 3.05
10% (w/v) ammonium persulfate 0.025
TEMED 0.005
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2.1.3.6 STAINING AND DESTAINING PAGE GELS 
 
Gels were stained for 30mins in solution containing 0.25g Coomassie Blue R-250 in 
45ml methanol, 45ml water and 10ml glacial acetic acid. Then destain gels in solution 
I (500ml methanol, 70ml glacial acetic acid and 880ml water) for repaid destaining, 
or in solution II (50ml methanol, 70ml glacial acetic acid ad 880ml water) for normal 
destaining. 
 
For proteins not detectable by Coomassie Blue staining, Bio-Rad Silver Staining kit 
was used. 
 
2.1.3.7 PERMANENT RECORD OF PAGE GELS 
 
Gels were photographed with Kodak Science digital camera DC120, and dried in 
between two pieces of cellophane paper. 
 
2.1.4 DETERMINATION OF PROTEIN CONCENTRATION 
 
The Bio-Rad protein assay kit based on the principle of Bradford (1976) was used for 
the determination of protein concentration. Bovine serum albumin (BSA) was used in 
the construction of the standard curve.  
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2.1.5 BIOINFORMATICS ANALYSIS 
 
Bioinformatics analysis of recombinant fusion proteins were carried out using 
bioinformatics tools available on the NUS website: www.bic.nus.edu.sg. In particular, 
the programs PRETTYSEQ and PEPSTATS were used. 
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2.2 EXPRESSION STUDIES OF H2S-GENERATING ENZYMES IN RAT 
THORACIC AORTA 
 
2.2.1 TOTAL RNA EXTRACTION 
 
Male Sprague-Dawley rats (280-300g) were killed by cervical dislocation and 
thoracic aorta weighing ~100mg/rat was dissected out, rinsed of blood in ice-cold 
saline and transferred to 1ml TRIzol reagent. The tissue was homogenized in ice and 
incubated for 5mins at room temperature. 0.2ml chloroform was added and reaction 
tubes were shaken vigorously for 15 sec and incubated for 2-3mins at room 
temperature. Centrifuge the samples at 12,000Xg, 15mins at 4°C. Transfer the upper 
aqueous phase to a fresh tube. Precipitate RNA from the aqueous phase by mixing it 
with 0.5ml isopropanol. Incubate samples at room temperature for 10mins and 
centrifuge at 12,000Xg, 10mins at 4°C. Remove supernatant and wash RNA pellet 
with 1ml 75% ethanol. Mix the sample by vortexing and centrifuge at 7,500Xg, 
5mins at 4°C. Remove the ethanol and air dry RNA pellet. Then dissolve RNA in 
20µl RNase-free water and incubate the solution at 55°C for 10mins.  
 
2.2.2 PRIMER DESIGN FOR CYSTATHIONINE-γ-LYASE (CSE) AND 
CYSTATHIONINE-β-SYNTHASE (CBS) 
 
Primers for detection of the H2S-generating enzymes CSE and CBS were designed 
using Primer Premier 4 from PREMIER Biosoft International. AY032875, rattus 
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norvegicus CSE mRNA, complete cds from Pubmed was used for the design of 
primers for CSE.  For the design of CBS primers, the rattus norvegicus CBS 
sequences NM_012522, M88344, M88345, M88346 and M88347 from Pubmed were 




Forward 5’-CAT GGA TGA AGT GTA TGG AGG C-3’ 
Reverse 5’-CGG CAG CAG AGG TAA CAA TCG-3’ 
 
CBS: 
Forward 5’-GAG CGA GCC GGA ACC TTG AAG C-3’ 
Reverse 5’-CAC CTA TCC ACC ACC GCC CTG TC-3’ 
 
2.2.3 ONE-STEP RT-PCR  
 
Qiagen One-step RT-PCR kit was used to check for mRNA expression of CSE and 
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Table 4. The reaction components for one-step RT-PCR of CSE and CBS were as 
follow: 
Component Volume / reaction Final Concentration 
Master Mix 
RNase-free water 11.5µl - 




10mM of each dNTP) 
0.8µ1 400µM of each dNTP 
Primer A 1.2µl 400µM 
Primer B 1.2µl 400µM 
QIAGEN OneStep RT-PCR 
Enzyme Mix 
0.8µ1 - 
Template RNA 0.5µ1 0.5µg/reaction 
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Table 5. The thermal cycler conditions for the one-step RT-PCR of CSE and CBS. 
Reverse transcription: 30min 50°C 
Initial PCR activation steps: 15min 95°C 
3-step-cycling   
Denaturation: 30sec 94°C 
Annealing: 30sec 60°C (CSE); 58°C 
(CBS) 
Extension: 30sec 72°C 
Number of cycles: 28 (CSE); 35 (CBS)  
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2.3 CONFIRMATION OF BACTERIAL CLONES 
(E. COLI BL21- pGEX-5X-1-αB30.2 & E. COLI BL21- pGEX-5X-1-βB30.2) 
  
2.3.1 EXTRACTION OF PLASMID DNA 
 
E. coli-BL21-pGEX-5X-1-αB30.2 or E. coli-BL21-pGEX-5X-1-βB30.2 (refer to 
Appendix) was innoculated into Luria broth containing 100µg/ml ampilcillin and 
grown overnight at 37°C. Plasmid was then extracted from the clones using Bio-
Rad’s Quantum Prep Plasmid Miniprep. 
 
2.3.2 POLYMERASE CHAIN REACTION AMPLIFICATION OF B30.2 
DOMAINS 
 
PCR was carried out using Qiagen’s Taq polymerase kit. Finnzymes dNTP mix and 
5’- and 3’- pGEX sequencing primers from Amersham Biosciences were used.  
 
5’-pGEX sequencing primer 
 5’-GGG CTG GCA AGC CAC GTT TGG TG-3’ 
 
3’-pGEX sequencing primer 
5’-CCG GGA GCT GCA TGT GTC AGA GG-3’ 
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Table 6. The reaction components for B30.2 PCR were as follow: 
Component Volume / reaction Final Concentration 
Master Mix 
10X Qiagen PCR buffer 10.0µl 1X 
dNTP mix (10mM each) 2.0µ1 200µM of each dNTP 
5’-pGEX sequencing primer 4.0µ1 0.2µM 
3’-pGEX sequencing primer 4.0µl 0.2µM 
Taq DNA polymerase 0.5µl 2.5 units/reaction 
Distilled water 59.5µ1 - 
Template DNA 20.0µ1 ≤1µg/reaction 
Total Volume 100.0µ1 - 
 
 
Table 7. The thermal cycler conditions for B30.2 PCR. 
Initial Denaturation: 3min 94°C 
3-step-cycling   
Denaturation: 1min 94°C 
Annealing: 1min 50°C 
Extension: 1min 72°C 
Number of cycles: 25  
Final extension: 10min 72°C 
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2.3.3 DNA CYCLE SEQUENCING OF PCR PRODUCTS 
 
DNA cycle sequencing was carried out using ABI Prism dRhodamine Terminator 
Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymarease, FS from 
Applied Biosystems. PCR products were purified for DNA sequencing using 
Microcon YM-100 Centrifugal unit.  
 
Table 8. The reaction components for B30.2 cycle sequencing were as follow: 
Reagent Quantity 
Terminator Ready Reaction Mix 8.0µl 
Template  
   purified PCR product, 10-30ng/µl 
6.0µ1 
5’-pGEX sequencing primer (3.2pmol) 1.3µ1 
MilliQ water 4.7µ1 
Total Volume 20.0µ1 
 
 
Table 9. The thermal cycler conditions for B30.2 cycle sequencing. 
Repeat for 25 cycles: 
Rapid thermal ramp to 96°C 
     96°C for 30secs 
Rapid thermal ramp to 50°C 
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     50°C for 15secs 
Rapid thermal ramp to 60°C 
     60°C for 4 mins 
Rapid ramp to 4°C and hold 
 
 
The cycle sequencing products were purified by ethanol precipitation and sent to 
National University Medical Institute Sequencing Laboratory for electrophoresis on 
ABI Prism 377. 
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2.4 PROTEIN PURIFICATION 
 
2.4.1 PURIFICATION OF STONUSTOXIN FROM SYNANCEJA HORRIDA 
 
The method of Poh et al., 1991 was used with some modifications. 
 
2.4.1.1 EXTRACTION OF S. HORRIDA VENOM 
 
Live stonefish (Synanceja horrida) was kept at 4 °C overnight and their dorsal fin 
excised (Figure 11). The 13 dorsal spines in the fin were pulled out and the venom 
was extracted from the venom sac using a 1ml syringe fitted with a G-21 gauge 
needle. The venom was lyophilized and stored at -80 °C until protein purification. 
 
2.4.1.2 SEPHACRYL S-200 HR GEL FILTRATION OF S. HORRIDA VENOM 
 
All operations were carried out at 4°C. 253.6mg lyophilized S. horrida venom was 
reconstituted in 1.0ml of 0.05M sodium phosphate buffer, pH 7.4 and centrifuged at 
12,000 g for 15mins to remove insoluble material. The supernatant was applied to a 
Sephacryl S-200 HR gel filtration column (1.6 X 100cm) previously equilibrated with 
the same buffer. Elution was carried out at a constant flow rate of 1ml/min and 3ml 
fractions were collected. The absorbance of the fractions was monitored at OD280. 
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2.4.1.3 DEAE BIO-GEL A (100-200 MESH) ANION EXCHANGE 
CHROMATOGRAPHY 
 
Peak 1 fractions from Sephacryl S-200 HR gel filtration was pooled together and 
loaded onto a DEAE Bio-Gel A (100-200 mesh) gel column (1.2 X 8.8 cm) that was 
pre-equilibrated with 0.05M sodium phosphate buffer, pH 7.4. The column was 
washed with 60ml of the same buffer before a linear sodium chloride gradient (0 to 
0.15M sodium chloride in 0.05M sodium phosphate buffer pH 7.4, 150ml) was 
initiated. 2.5ml fractions were collected and their absorbance monitored at OD280. 
 
2.4.1.4 STORAGE OF PURIFIED STONUSTOXIN 
 
Protein concentration of purified Stonustoxin was determined and stored at 
appropriate aliquots at -80°C after purification prior to usage. 
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Figure 11. Extraction of Synanceja horrida venom. 
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2.4.2 PURIFICATION OF GST, GST-αB30.2 AND GST-βB30.2 PROTEINS 
 
For references, refer to GST Gene Fusion System, 3rd edition, Revision 2, Amersham 
Pharmacia Biotech, 1997; GSTrap FF, 1ml and 5ml Instruction Manual, Amersham 
Biosciences, 1996. 
 
2.4.2.1 INDUCTION OF PROTEIN EXPRESSION IN BACTERIAL CELLS 
 
E. coli BL21-pGEX-5X-1, E. coli BL21-pGEX-5X-1-αB30.2 or E. coli BL21-pGEX-
5X-1-βB30.2 (refer to Appendix) was inoculated in 10ml Luria Broth (LB) broth 
containing 100µg/ml of ampicillin and incubated for 12-15 hours overnight at 37°C 
with vigorous shaking. The overnight culture was diluted 1:100 into 1l fresh pre-
warmed LB broth containing 100µg/ml ampicillin and grown at 30°C with shaking 
until OD600 reaches 0.7. IPTG was added to a final concentration of 0.1mM and the 
culture was incubated with shaking at 30°C for 4 hours. The culture was then 
centrifuged at 7,700X g for 10 min at 4°C. The supernatent was discarded and the 
pellet was stored at -20°C.  
 
Note: To ensure adequate aeration of the bacterial cultures, culture flasks were filled 
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2.4.2.2 CELL LYSIS 
 
Suspend frozen cell pellet (from 1l bacterial culture; 2.4.2.1) in 50ml ice-cold 1X 
phosphate buffered saline (PBS). Disrupt suspended cells in ice using a sonicator at 
strength 3, 10s pulse, 10s stop for a total of 8 min. Centrifuge sonicate at 12,000X g 
for 10 min at 4°C. Transfer the supernatent to a fresh container for purification of 
soluble GST, GST-αB30.2 or GST-βB30.2. Store the cell debris at -20 °C for 
possible purification of GST, GST-αB30.2 or GST-βB30.2 from inclusion bodies. 
 
2.4.2.3 AFFINITY PURIFICATION OF SOLUBLE GST, GST-αB30.2 OR 
GST-βB30.2 
 
Bacterial supernatent containing soluble GST, GST-αB30.2 or GST-βB30.2 proteins 
obtained from 2.4.2.2 was filtered through a 0.45µm Millipore filter. Fast 
Performance Liquid Chromatography (FPLC) was then employed for the purification 
of GST, GST-αB30.2 or GST-βB30.2. The filtered bacterial supernatant was applied 
to a 5ml GSTrapFF column previously equilibrated with 1X PBS. Binding of proteins 
to the GSTrappFF column occurs at a rate of 5ml/min. The column was washed 
thoroughly with 1X PBS (15 column volumes; 10ml/min) before being eluted with 
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2.4.2.4 ATTEMPTED REMOVAL OF GRO-EL FROM SOLUBLE GST-
αB30.2 AND GST-βB30.2 USING AN ATP WASH BUFFER 
 
Re: Trends in Genetics (1996) vol. 12, no. 6, pg 209-210. A method for separation of 
GST fusion proteins from co-purifying GroEL.  
 
GST-αB30.2 or GST-βB30.2 was bound to 5ml GSTrapFF column as normal 
(section 2.4.2.3), and equilibrated with buffer 1 (50mM TEA pH 7.5, 50mM KCl, 
20mM MgCl2). After equilibration, the column was washed with 20 column volumes 
of 5mM adenosine 5’ triphosphate (ATP) in buffer 1 (10ml/min). The column was 
then equilibrated in buffer 2 (50mM TEA, pH 8), and eluted with 50mM reduced 
glutathione in buffer 2 (2ml/min; 1ml fractions collected).  
 
2.4.2.5 ATTEMPTED REMOVAL OF GRO-EL FROM SOLUBLE GST-
αB30.2 USING AN ATP WASH BUFFER AND GRO-ES 
 
Re: Trends in Genetics (1996) vol. 12, no. 6, pg 209-210. A method for separation of 
GST fusion proteins from co-purifying GroEL.  
 
GST-αB30.2 was bound to 5ml GSTrapFF column as normal (section 2.4.2.3), and 
equilibrated with buffer 1 (50mM TEA pH 7.5, 50mM KCl, 20mM MgCl2). After 
equilibration, the column was washed with 50 column volumes of 5mM adenosine 5’ 
triphosphate (ATP) and 2.5µM GroES in buffer 1 (10ml/min). The column was then 
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equilibrated in buffer 2 (50mM TEA, pH 8), and eluted with 50mM reduced 
glutathione in buffer 2 (2ml/min; 1ml fractions collected).  
 
2.4.2.6 PURIFICATION OF GST-αB30.2 AND GST-βB30.2 FROM 
INCLUSION BODIES 
 
2.4.2.6.1 METHOD 1 
 
Re: BioTechniques (1992) vol. 13, no. 6, pg 856-857. An improved procedure for 
purification of protein fused to glutathione-S-transferase. 
 
Cell debris from the clarification of sonicated bacterial cells (from section 2.4.2.2) 
was suspended in 25ml 1.5% N-lauroylsarcosine, 25mM triethanolamine, 1mM 
EDTA, pH 8.0 and mixed for 10mins at 4°C. Centrifuge the suspension at 7,750X g; 
4°C. Collect the supernatant and add Triton X-100 and CaCl2 at final concentrations 
of 2% and 1mM respectively. Then add 25ml 1X PBS to the supernatant. Proceed 
with FPLC purification after filtering the supernatant through a 0.45µm Millipore 
filter. Binding of the proteins to the GSTrappFF 5ml column occurs at a rate of 5 
ml/min. The column was washed thoroughly with 1X PBS (50 column volumes; 
10ml/min) before elution with 50mM Tris-HCl, 10mM reduced glutathione at pH 8.0 
(2ml/min; 1ml fractions collected). 
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2.4.2.6.2 METHOD 2 
 
Re: Protein Expression and Purification (1999) vol. 16, pg331-339. Penicillin-binding 
protein 2a of Streptococcus pneumoniae: Expression in Escherichia coli and 
purification and refolding of inclusion bodies into a soluble and enzymatically active 
enzyme. 
 
Cell debris collected from section 2.4.2.2 was resuspended in 70 ml of 50 mM Tris-
HCl, pH 7.5, 1 mM EDTA, and 100 mM KCl (buffer A), and centrifuged at 12,000g 
for 10 min. This process was repeated five to six times. The pellet was collected, 
resuspended in 70 ml buffer A, and centrifuged at 760g for 10 min. The supernatent 
fraction was collected and designated as inclusion bodies preparation. The inclusion 
bodies preparation was centrifuged at 12,000g for 10 min. The resulting pellet was 
resuspended in 40 ml of 8M urea and then diluted gradually with 70 ml of buffer A 
until a small amount of white precipitate appeared. This preparation was centrifuged 
at 12,000g for 10 min, and the pellet was discarded. The supernatent fraction was 
dialyzed (10 kDa cutoff dialysis tubing) in 4 liters of buffer A at 4 °C overnight and 
then another 4 liters of buffer A for 10 hours. After dialysis, the protein preparation 
was centrifuged at 12,000g for 10 min to remove any remaining insoluble material. 
The supernatent fraction was desalted using Microcon (10 kDa cutoff membrane) and 
the protein retentate was redissolved in 1X PBS. 
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2.4.2.7 BUFFER EXCHANGE & STORAGE OF PURIFIED PROTEINS 
 
Purified proteins were resuspended in 1X PBS using Centricon YM-10. The proteins 
were then quantitated and stored at appropriate aliquots at -80°C. 
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2.5 WESTERN BLOTTING: IMMUNORECOGNITION OF GST-αB30.2 AND 
GST-βB30.2 BY POLYCLONAL ANTIBODIES DIRECTED AGAINST SNTX 
 
Electrophoresce proteins using SDS-PAGE. Prewet a sheet of polyvinylidene 
difluoride (PVDF) membrane in 100% methanol (10sec). Then wash the membrane in 
distilled water for 5 min before equilibrating it in protein transfer buffer (25 mM Tris, 
190 mM glycine, 20% MeOH) for at least 10 min. Rinse the gel obtained from SDS-
PAGE) with protein transfer buffer. Assemble the electroblotting casette and transfer 
the proteins from the gel to the membrane at 400mV, 50mA for 1 hr. Following 
transfer, mark the orientation of the gel. Rinse the PVDF membrane with 1X PBS, 
and block non-specific binding sites on the membrane by incubating it with 0.1%(v/v) 
Tween 20, 5%(w/v) dried skim milk in 1X PBS for 1 hr. After that, rinse the 
membrane twice with PBS-T (0.1%(v/v) Tween 20 in 1X PBS) followed by 
subsequent washing with excess PBS-T for 2 X 10 mins. Incubate the membrane for 
1 hr with polyclonal anti-SNTX antibody obtained from rabbits by the subcutaneous 
injection of native SNTX (120µg) emulsified in complete Freund’s adjuvant. Rinse 
the membrane again with PBS-T followed by more thorough washing with an excess 
of PBS-T for 2 X 10 mins. Then, incubate the membrane with anti-rabbit antibodies 
for 1 hr, followed by a similar washing step as above. Apply ECL detection reagents 
that have been pre-mixed in equal volumes to the membrane. Expose the membrane 
to an x-ray film. 
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2.6 ORGAN BATH STUDIES  
 
As reference, refer to Current Protocols in Pharmacology, 2001. 
 
2.6.1 KREBS PHYSIOLOGICAL SOLUTION 
 
Krebs physiological solution (in mM): NaCl 118; KCl 4.8; KH2PO4 1.2; CaCl2 2.5; 
NaHCO3 25; MgSO4 2.4; D-(+)-glucose 11.0. The solution was aerated vigorously 
with 5% CO2; 95% O2 for ten minutes prior usage. Throughout the entire experiment, 
Krebs solution containing tissue was bubbled with 5% CO2; 95% O2. 
 
Table 10. Preparation of Krebs’ physiological solution. 
 
Salt NaCl KCl CaCl2 MgSO4 KH2PO4 NaHCO3 Glucose
Stock 
Concentration 
25% 10% 10% 10% 5% - - 
Volume (ml) (ml) (ml) (ml) (ml) (g) (g) 
2 litre 55.2 7.2 5.6 5.8 6.4 4.2 4.0 
3 litre 82.8 10.8 8.4 8.7 9.6 6.3 6.0 
4 litre 110.4 14.4 11.2 11.6 12.8 8.4 8.0 




Chapter 2 Materials & Methods 
100 
2.6.2 TISSUE PREPARATION 
 
Male Sprague-Dawley (SD) rats (250-300g) were killed by cervical dislocation. The 
thoracic wall was cut open and thoracic aorta (immediately anterior to the spine) was 
extracted, washed of blood, cleaned of surrounding connective tissue and cut into 
rings of approximately 2 mm in length Figure 12. Care was taken not to pull on the 
aorta and not to damage the endothelium during the entire process. Aortic rings were 
gently hooked to a string and a metal hook, and transferred to a 2.5 ml organ bath 
filled with Krebs solution aerated with 5% CO2; 95% O2. The aortic ring was 
mounted such that its tension was measured with a force transducer (ADInstruments 
model: MLT0201) that can measure isometric forces in the range of 5mg to 25g 
weight. The basal tone of the aortic ring was set to a tension of 1.0 - 1.5g and the 
aortic rings were allowed to stabilize for 1 hr. The organ bath was maintained at 
37± 1°C throughout the entire experiment. Figure 13 shows a typical organ bath set-
up. 
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Figure 12. Pictorial representation of the isolation and processing of Sprague Dawley (SD) rat’s aorta for organ bath studies. 
Thoracic aorta 
Vena Cavae Esophagus 
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Figure 13.  A typical organ bath set-up. The aortic ring was mounted in an organ bath filled with pre-warmed 37°C Krebs solution 
bubbled with 5% CO2; 95% O2. The tension of the aortic ring was monitored by an isometric force transducer connected to an 
ADInstrument PowerLab that is connected to a computer. The tension of the ring was monitored in real-time by the ADInstrument 
Chart 5 software.
Krebs solution out 
Reservoir of 37 ºC 
water 
37 ºC water in 
5% CO2; 95% O2 
Isometric Force Transducer 
Reservoir of Krebs 
solution 
Organ bath 
Krebs solution in 
37 ºC water out 
Hook and String 
(wound round 
transducer) 
Metal Rod with Hook 
ML750 PowerLab/4SP 
Real-time monitoring on Chart 5 
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2.6.3 PRELIMINARY EXPERIMENTS 
 
2.6.3.1 Testing the Response of 2mm Thoracic Aortic Rings to Cumulative 
Concentrations of L-phenylephrine hydrochloride (PE) 
 
Table 11. Table showing the cumulative concentration of PE used in 2.5ml organ 
baths to contract 2mm thoracic aortic rings. The amount of drug to add each time to 
achieve the cumulative concentration was shown. The total volume of drug added to 






Vol of 0.01M Stock 
(ul) 
Vol of 0.0001M Stock 
(ul) 
0.015 0.015 - 0.375 
0.02 0.035 - 0.5 
0.04 0.075 - 1 
0.08 0.155 - 2 
0.16 0.315 - 4 
0.32 0.635 - 8 
0.64 1.275 - 16 
1.28 2.555 0.32 - 
2.56 5.115 0.64 - 
5.12 10.235 1.28 - 
10.24 20.475 2.56 - 
Total Volume 36.675 µl (i.e. 1.467% of organ bath’s volume) 
 
 
2.6.3.2 Testing the Response of 0.32µM PE- precontracted 2mm Thoracic Aortic 
Rings to Cumulative Concentrations of Acetylcholine Chloride (Ach) 
 
Table 12. Table showing the cumulative concentration of Ach used in 2.5ml organ 
baths to relax the 0.32µM PE-precontracted 2mm thoracic aortic rings. The amount of 
Chapter 2 Materials & Methods 
104 
drug to add each time to achieve the cumulative concentration was shown. The total 







Vol of 0.01M Stock 
(ul) 
Vol of 0.0001M Stock 
(ul) 
0.015 0.015 - 0.375 
0.02 0.035 - 0.5 
0.04 0.075 - 1 
0.08 0.155 - 2 
0.16 0.315 - 4 
0.32 0.635 - 8 
0.64 1.275 - 16 
1.28 2.555 0.32 - 
2.56 5.115 0.64 - 
5.12 10.235 1.28 - 
10.24 20.475 2.56 - 





Before actual experimentation, 2mm thoracic aortic rings were checked for their 
responsiveness and endothelial integrity. 0.32µM PE-precontracted aortic rings that 
exhibit greater or equal to 70% vasorelaxation with 2.56µM Ach were used for 
















Figure 14. Test of 2mm thoracic aortic rings with 0.32µM L-phenylephrine and 2.56µM acetylcholine before actual 
experimentation. 0.32µM L-phenylephrine precontracted aortic rings exhibiting greater or equal to 70% vasorelaxation with 
2.56µM acetylcholine were used for further experimentation after a washing (with fresh Krebs) and stabilization period. Otherwise, 

















0.32µM L-phenylephrine 2.56µM Acetylcholine 
≥ 70% vasorelaxation 
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2.6.4.1 Response of 0.32µM PE- precontracted 2mm Rat Thoracic Aortic Rings to 
Cumulative Concentrations of Stonustoxin (P-C protein) 
 
Table 13. Table showing the cumulative concentration of Stonustoxin (F68 of P-C 
protein) used in 2.5ml organ baths to relax 0.32µM PE-precontracted aortic rings. The 
amount of drug to add each time to achieve the cumulative concentration was shown. 










Vol of 151.131 
ng/µl Stock (ul) 
Vol of 1:1 diluted Stock 
i.e. 75.566 ng/µl Stock (ul) 
10 25 10 - 0.33 
10 25 20 - 0.33 
20 50 40 0.33 - 
40 100 80 0.66 - 
80 200 160 1.32 - 
160 400 320 2.65 - 
320 800 640 5.29 - 
Total Volume 36.675 µl (i.e. 1.467% of organ bath’s volume) 
 
 
2.6.4.2 Response of 0.32µM PE- precontracted 2mm Thoracic Aortic Rings to 
Cumulative Concentrations of Recombinant Proteins 
 
Table 14. Table showing the cumulative concentration of recombinant proteins used 
in 2.5ml organ baths to relax 0.32µM PE-precontracted aortic rings.(Note: The total 
volume of drug added to an organ bath should not exceed 10% of the organ bath’s 
volume.) 





2.6.4.3 Inhibitor studies 
 
To elucidate the mechanisms leading to vasorelaxation of thoracic aorta by 
stonustoxin, experiments were conducted with various inhibitors (PAG, BCA, L-
NAME, etc) as shown in Figure 15. 
 
2.6.5 DATA ANALYSIS 
 
The results were expressed as mean ± SE. All concentration-response curves were 
fitted with a Hill equation, from which IC50 was calculated. Student’s t-test for 
unpaired samples was used to compare the mean difference between control and 
tested groups. For comparison of differences between control and experimental 



























Figure 15. Experimental Protocol to see the effect of various inhibitors on vasorelaxation of 0.32µM L-phenylephrine precontracted 
aortic rings by Stonustoxin. 
0.32µM L-phenylephrine 
2.56µM Acetylcholine
≥ 70% vasorelaxation 
Inhibitor / Control (1 hr)
Wash Out & Stabilisation
0.32µM L-phenylephrine
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3.1 PURIFICATION OF STONUSTOXIN FROM SYNANCEJA HORRIDA 
 
3.1.1 SEPHACRYL S-200 HR GEL FILTRATION OF S. HORRIDA VENOM 
 
Gel filtration of crude S. horrida venom yielded three major protein peaks (P1, P2 
and P3; Figure 16) as was obtained previously by Poh et al., 1991. Fractions 
constituting P1 were pooled together for the next chromatographic step. P1 
(containing 8.7mg protein) accounted for 38.7% of the total venom protein loaded 
onto the gel filtration column. 
 
3.1.2 DEAE BIO-GEL A (100-200 MESH) ANION EXCHANGE 
CHROMATOGRAPHY OF P1 
 
Anion-exchange chromatography of P1 yielded 3 protein peaks (P-A, P-B and P-C; 
Figure 17) instead of 4 protein peaks that were obtained by Poh et al., 1991. Instead 
of using 4 days as was used by Poh et al., 1991 for this purification step, one day is 
sufficient using the method described in Section 2.4.1.3. 
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Figure 16. Sephacryl S-200 HR (1.6 X 100 cm)  gel filtration of 253.6mg lyophilized crude S. horrida venom suspended in 1ml of 
0.05M sodium phosphate buffer, pH 7.4 (flow rate: 1ml/min). Elution buffer was 0.05M sodium phosphate buffer, pH 7.4. 3 ml 
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Figure 17. DEAE Bio-gel A (100-200mesh) anion-exchange chromatography of P1 (column dimension: 1.2 X 8.8 cm). 8.7mg protein 
was loaded onto the column and washed with 60ml of 0.05M sodium phosphate buffer before a linear sodium chloride gradient 
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3.1.3 POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) OF P-C 
 
SDS-PAGE of F68 under both reducing (Figure 18) and non-reducing (results not 
shown) conditions shows 2 protein bands of ~71 and 79kDa. The protein in F68 that 
is made up of 2 subunits linked via non-sulfide bonds is probably Stonustoxin 
(SNTX). SNTX has a molecular weight of 148kDa made up of two subunits SNTX-α 
and SNTX-β with molecular weights of 71 and 79kDa respectively (Poh et al., 1991). 
The subunits have been shown to be linked via non-disulfide linkages (Ghadessey et 
al., 1996). To confirm that the protein in F68 was indeed SNTX, it was tested for its 
vasorelaxing property (see Section 3.3).  
 
Figure 18. Polyacrylamide gel electrophoresis of fraction 68 of P-C in 10% SDS-
PAGE gel under reducing conditions. M stands for molecular weight marker. 
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3.1.4 YIELD OF STONUSTOXIN FROM PURIFICATION 
 
Approximately 3mg of SNTX was obtained from the purification process, i.e. 13.3% 
of total venom protein used for purification. The purification method by Poh et al., 
1991 resulted in purification of SNTX which is 9 % of the total venom protein that 
was used for purification. 
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3.2 PRELIMINARY ORGAN BATH STUDIES 
 
3.2.1 Response of 2mm Rat Thoracic Aortic Rings to Cumulative Concentrations of 
L-phenylephrine hydrochloride (PE) 
 
Cumulative addition of PE to 2mm rat thoracic aortic rings led to progressive 
vasoconstriction (Figure 19). The cumulative dose-vasoconstriction curve produced 
by PE has an IC50 of 0.0390µM and an EC85 of 0.32µM. 0.32µM of PE was used to 
precontract 2mm rat thoracic aortic rings prior to any vasorelaxation experiments.  
 
3.2.2 Response of 0.32µM PE- precontracted 2mm Rat Thoracic Aortic Rings to 
Cumulative Concentrations of Acetylcholine Chloride (Ach) 
 
When the vasoconstriction response of 2mm rat thoracic aortic rings to 0.32µM PE 
has reached a stable plateau, Ach was added cumulatively. Cumulative addition of 
Ach to the 0.32µM PE-precontracted aortic rings led to progressive vasorelaxation 
(Figure 20). The cumulative dose-vasorelaxation curve produced by Ach has an IC50 
of 0.0824uM, and an EC85 of 2.56µM.  
 
3.2.3 Conclusive Remarks 
 
Before any 2mm rat thoracic aortic rings was used for experimentation, it was tested 
with 0.32µM PE and 2.56µM Ach. 0.32µM PE-precontracted aortic rings that exhibit 
Chapter 3 Results 
116 
at least 70% vasorelaxation with Ach were defined to be endothelium-intact and were 
used for further experimentation (Figure 14). 
 
Chapter 3 Results 
117 
Figure 19. Vasoconstriction of 2mm rat thoracic aortic rings by cumulative concentrations of L-phenylephrine. (a) Experimental 













EC50 = 0.03898 uM L-phenylephrine
LogEC50 = -1.409 uM L-phenylephrine
Log [Cumulative Concentration of L-phenylephrine (uM)]
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EC50 = 0.08238 uM Acetylcholine
LogEC50 = -1.084 uM Acetylcholine
*0.32uM L-phenyleprine ~ EC83
EC85 ~ 2.56uM Acetylcholine
Log [Cumulative Concentration of Acetylcholine (uM)]
 
Figure 20. Response of 0.32µM L-phenylephrine precontracted 2mm thoracic aortic rings to cumulative concentration of 
acetylcholine. (a) Experimental profile obtained. (b) Dose-response curve. 
(a) 
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3.3 VASORELAXATION BY STONUSTOXIN 
 
3.3.1 Concentration-dependent vasorelaxation of 2mm, endothelium-intact, 0.32µM 
PE-precontracted thoracic aortic rings   
 
To confirm that the purified protein in F68 of P-C (Section 3.1.3) was indeed 
stonustoxin, the protein was added cumulatively to endothelium-intact, 2mm, 0.32µM 
PE-precontracted rat thoracic aortic rings in organ bath studies to check whether if it 
causes vasorelaxation. Endothelium-intact aortic rings were defined as 0.32µM PE-
precontracted 2mm thoracic aortic rings that exhibit at least 70% vasorelaxation with 
Ach (Figure 14). At concentrations ranging between 10 – 320ng/ml, the purified 
protein caused concentration-dependent vasorelaxation of the precontracted aortic 
rings, with logIC50 of 2.02 ± 0.00434ng/ml and maximum vasorelaxation of 49.1 ± 
0.256 % (Figure 21).  
 
3.3.2 Nitric oxide Involvement in SNTX-induced vasorelaxation 
 
Earlier observations by Low et al., 1993 and Sung et al., 2002 showed that SNTX-
induced vasorelaxation of precontracted aorta involve nitric oxide. To further confirm 
the identity of the purified protein (See Section 3.1.3), the protein was added to 2mm, 
endothelium-intact, 0.32µM PE-precontracted thoracic aortic rings that has been pre-
incubated with 10µM L-NAME for 1hr. Preincubation of the aortic rings with 10 µM 
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L-NAME completely abolished the vasorelaxant effect of Stonustoxin on the PE-
precontracted aortic rings (Figure 22).  
 
3.3.3 Conclusive remarks 
 
Together with the PAGE studies in Section 3.1.3, the experiments in this section 
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 Figure 21. Response of 0.32µM L-phenylephrine precontracted 2mm thoracic aortic rings to cumulative concentration of Stonustoxin 






















































Cumulative Stonustoxin Concentration (ng/ml) 
10 20 40 80 160 320 640
1 min
Chapter 3 Results 
122 
Figure 22. Nitric oxide involvement in SNTX-mediated vasorelaxation of 0.32µM PE-precontracted, endothelium-intact, 2mm 
thoracic aortic rings. The experimental profiles obtained in the presence of saline control or the nitric oxide-synthase inhibitor, L-














0.32µM L-phenylephrine 0.32µM L-phenylephrine
2.56µM Acetylcholine 
≥ 70% vasorelaxation 
Wash Out & Stabilisation
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Cumulative Stonustoxin Concentration (ng/ml) 
SNTX + Saline 
 
SNTX + 10µM L-NAME  
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3.4 EXPRESSION STUDIES OF H2S-GENERATING ENZYMES IN RAT 
THORACIC AORTA 
 
Thoracic aorta weighing ~100mg was obtained from each rat weighing ~280-300g. 
For all RNA extractions, ~0.2µg of total RNA was obtained for 100mg of thoracic 
aorta. One-step RT-PCR using primers for the H2S-generating enzymes 
cystathionine-γ-lyase (CSE) and cystathionine-β-synthase (CBS) showed that CSE 
but not CBS is expressed in rat thoracic aorta (Figure 23).  
 
Figure 23. Expression of CSE but not CBS in rat thoracic aorta. Agarose gel 
electrophoresis of one-step RT-PCR products amplified using CSE and CBS primers 
and total RNA extracted from rat thoracic aorta. M is Promega’s 100bp DNA ladder. 
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3.5 INVOLVEMENT OF HYDROGEN SULFIDE (H2S) IN SNTX-INDUCED 
VASORELAXATION 
 
Stonustoxin induced a concentration-dependent vasorelaxation of endothelium-intact, 
2mm, 0.32µM PE-precontracted thoracic aortic rings (logIC50 = 2.02 ± 0.00434 
ng/ml). Using D, L-proparglyglycine (PAG) and β-cyano-L-alanine (BCA), 
irreversible and competitive inhibitors respectively of the H2S-generating enzyme 
cystathionine-γ-lyase (CSE) in organ bath studies showed that H2S is involved in 
SNTX-induced vasorelaxation of the PE-precontracted thoracic aortic rings (Figure 
24; Table 16).  
 
Pretreatment of the aortic rings with 1mM PAG for 1h prior to subsequent 
vasorelaxation of the endothelium-intact, PE-contracted aortic rings with Stonustoxin, 
shifted the logIC50 of Stonustoxin to the right i.e. logIC50 = 2.04 ± 0.00313 ng/ml (P < 
0.05) (Figure 24a). Similar results were obtained with 1mM BCA, with logIC50 of 
Stonustoxin shifted to the right, i.e. 2.14 ± 0.00310 ng/ml (P < 0.05) (Figure 24b). In 
addition, the maximum vasorelaxation induced by Stonustoxin was decreased from 
49.1 ± 0.256 % to 39.0 ± 0.131 % in the presence of 1mM PAG (P < 0.05) (Table 
16). In the presence of 1mM BCA, the maximum vasorelaxation induced by 
Stonustoxin is decreased to 38.8 ± 0.133% (P < 0.05). The maximum tension of the 
aortic rings induced by 0.32µM L-phenylephrine after pretreatment with inhibitors is 
not significantly different from the control (P > 0.05). 
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Figure 24. The effect of (a) D, L-proparglyglycine (PAG) and (b) β-cyano-L-alanine (BCA) on SNTX-induced vasorelaxation of 
2mm, endothelium-intact, 0.32µM PE-precontracted thoracic aortic rings. The original records from experiments (inhibitor & control) 
conducted with segments of one aortae (top) and data represented as mean ± SEM (bottom) are shown. (c) Combination of (a) and (b). 
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Table 15. Table showing the effect of PAG and BCA on the logIC50 and maximum 
vasorelaxation induced by Stonustoxin on endothelium-intact, 2mm, 0.32µM PE-
precontracted thoracic aortic rings. 
 
Experimental Group LogIC50 (ng/ml) Maximum Vasorelaxation (%) 
SNTX + Ctl 2.022 ± 0.004342 49.05 ± 0.2564 
SNTX + 1mM PAG 2.041 ± 0.003128 38.93 ± 0.1312 
SNTX + 1mM BCA 2.136 ± 0.003100 38.81 ± 0.1333 
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3.6 SYNERGY BETWEEN HYDROGEN SULFIDE (H2S) & NITRIC OXIDE 
(NO) IN SNTX-INDUCED VASORELAXATION 
 
The use of L-NAME and CSE inhibitors in organ bath studies showed that H2S and 
NO work in synergy to cause SNTX-mediated vasorelaxation of endothelium-intact, 
2mm, 0.32 µM PE-precontracted thoracic aortic rings (Figure 25; Table 17).  
 
Since the preincubation of the aortic rings with 10µM L-NAME for 1hr completely 
abolished the vasorelaxant effect of SNTX on the PE-precontracted aortic rings (see 
Section 3.3.2), aortic rings were pre-incubated with 1µM L-NAME instead. In the 
presence of 1 µM L-NAME, the logIC50 of Stonustoxin (logIC50 = 2.02 ± 0.00434 
ng/ml) is shifted to the right to logIC50 = 2.26 ± 0.0107 ng/ml (P < 0.05) (Figure 25) 
and the maximum vasorelaxation is decreased from 49.1 ± 0.256% to 31.4 ± 0.559% 
(P < 0.05) (Table 17). 1µM L-NAME is thus used together PAG or BCA to check for 
synergism between NO and H2S in SNTX-induced vasorelaxation of precontracted 
thoracic aortic rings.  
 
In the presence of 1mM PAG and 1 µM L-NAME, the vasorelaxation of PE-
precontracted aortic strips is completely abolished (Figure 25a). In the presence of 
1mM BCA and 1µM L-NAME, the logIC50 of Stonustoxin is decreased to 2.38 ± 
0.00652ng/ml and the maximum vasorelaxation by Stonustoxin decreased to 25.6 ± 
0.301% (Figure 25b; Table 17). Note that the maximum tension of the aortic rings 
induced by 0.32µM L-phenylephrine after pretreatment with inhibitors is not 
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significantly different from the control (P > 0.05). Since the use of 1µM L-NAME 
with 1mM PAG or 1mM BCA exhibits a greater inhibition of SNTX-relaxation of 
PE-precontracted aortic rings than when the inhibitors are used individually, this 
indicated synergism between H2S and NO in mediating the vasorelaxing effect of 
SNTX. 
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Figure 25. Synergism between H2S and NO in SNTX-induced vasorelaxation. (a) 
Synergistic inhibition by (a) PAG and L-NAME and (b) BCA and L-NAME on 
SNTX-induced vasorelaxation of endothelium-intact, 2mm, 0.32µM PE-
precontracted thoracic aortic rings. * p < 0.05 vs. saline control. 
 
(a) 
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SNTX + 1uM L-NAME (n = 5)
SNTX + 1mM PAG (n = 9)
SNTX + 1mM PAG + 1uM L-NAME (n = 5)
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Table 16. Table showing the synergistic effect of PAG + L-NAME and BCA + L-
NAME on the logIC50 and maximum vasorelaxation induced by Stonustoxin on 
endothelium-intact, 2mm, 0.32µM PE-precontracted thoracic aortic rings. 
 
 
Experimental Group LogIC50 (ng/ml) Maximum Vasorelaxation (%) 
SNTX + Ctl 2.022 ± 0.004342 49.05 ± 0.2564 
SNTX + 1µM L-NAME 2.255 ± 0.01073 31.38 ± 0.5588 
SNTX + 1mM PAG 2.041 ± 0.003128 38.93 ± 0.1312 
SNTX + 1mM PAG + 
1µM L-NAME 
NA NA 
SNTX + 1mM BCA 2.136 ± 0.003100 38.81 ± 0.1333 
SNTX + 1mM BCA + 
1µM L-NAME 
2.379 ± 0.006519 25.62 ± 0.3006 
NA: not applicable 
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3.7 EFFECT OF L-CYSTEINE ON THORACIC AORTIC RINGS  
 
Teague et al. (2001) showed that 1mM L-Cysteine was able to cause a slowly 
developing decline in the size of BCA-augmented twitch response of guinea pig 
ileum. Cheng et al. (2004) also showed that 1mM L-Cysteine increased endogenous 
H2S production by 6-fold in rat mesenteric artery tissues and decreased contractility 
of mesenteric artery beds. As a result, 1mM L-cysteine (Sigma catalog no. C7352) 
was used to see whether it could reverse the inhibition by BCA on SNTX-induced 
vasorelaxation of 2mm, endothelium-intact, 0.32µM PE-precontracted thoracic aortic 
rings. However, when 1mM L-Cysteine was added to endothelium-intact, resting 
thoracic aortic rings preincubated for 30mins with BCA or control saline, an 
immediate transient increase in tone of the thoracic aortic rings was observed in all 
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Figure 26. Effect of 1mM L-cysteine (free base) on endothelium-intact, resting thoracic aortic rings that was preincubated with 
Saline or 1mM BCA.  
0.32µM L-phenylephrine 
2.56µM Acetylcholine
Saline or 1mM BCA
Wash Out & Stabilisation
≥ 70% vasorelaxation
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3.8 CONFIRMATION OF BACTERIAL CLONES 
(E. COLI BL21- pGEX-5X-1-αB30.2 & E. COLI BL21- pGEX-5X-1-βB30.2) 
 
The B30.2 domain of both SNTX-α and SNTX-β have been amplified by PCR and 
cloned into pGEX-5X-1 producing pGEX-5X-1-αB30.2 and pGEX-5X-1-βB30.2 
respectively (refer to Appendix). The recombinant plasmids were transformed into E. 
coli BL21(DE3) thus producing E. Coli BL21-pGEX-5X-1-αB30.2 and E. Coli 
BL21-pGEX-5X-1-βB30.2. The bacterial clones were checked before being induced 
to synthesize recombinant B30.2 domain-containing proteins for pharmacological 
experiments (Sections 3.10 & 3.11).  
 
3.8.1 POLYMERASE CHAIN REACTION AMPLIFICATION OF B30.2 
DOMAINS 
 
PCR amplification of the B30.2 domain in pGEX-5X-1-αB30.2 and pGEX-5X-1-
βB30.2 using 5’-pGEX sequencing primer and 3’-pGEX sequencing primer produced 
expected PCR products that are 700bp in size (Figure 27).  
 
3.8.2 DNA CYCLE SEQUENCING OF PCR PRODUCTS 
 
To confirm that the B30.2 domains have been cloned in the correct frame into pGEX-
5X-1, and to check that no mutations have occurred to the B30.2 domains during 
storage of E. Coli BL21-pGEX-5X-1-αB30.2 and E. Coli BL21-pGEX-5X-1-βB30.2, 
Chapter 3 Results 
136 
DNA cycle sequencing was done. DNA sequencing of the amplified αB30.2 PCR 
product (Figure 28) and βB30.2 PCR product (Figure 29) shows that the B30.2 
domains has been cloned in frame with the start codon of GST in pGEX-5X-1. No 
DNA mutations have occurred to the B30.2 domain in pGEX-5X-1-αB30.2. On the 
other hand, the B30.2 domain in pGEX-5X-1-βB30.2 has got 4 point mutations. One 
out of the 4 point mutations is not conserved. In 2 cases, UCA (Ser) has replaced 
UCC (Ser). In another case, UUG (Leu) has replaced CUG (Leu). For the non-
conserved point mutation, UAU (Tyr) has replaced CAU (His). Tyr is a hydrophobic 
amino acid while his is a basic amino acid. Despite one non-conserved point mutation 
in the B30.2 domain of pGEX-5X-1-βB30.2, E. Coli BL21-pGEX-5X-1-βB30.2 was 
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Figure 27. PCR amplification of the B30.2 domains in E. coli BL21- pGEX-5X-1-






















E. COLI BL21-  
pGEX-5X-1-αB30.2 bp 
E. COLI BL21-  
pGEX-5X-1-βB30.2 
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Figure 28. DNA sequencing of PCR-amplified αB30.2 PCR product (see Section 3.8.1). The αB30.2 domain has been cloned in frame 
with the start codon of GST in pGEX-5X-1. No DNA mutations have occurred to the B30.2 domain.  
BamHI cleavage site 
B30.2 Domain Vector 
SalI cleavage site 
Stop Codon 
Thrombin cleavage site 
Vector 
Insert 
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Figure 29. DNA sequencing of the amplified βB30.2 PCR product (see Section 3.8.1). The βB30.2 domain has been cloned in frame 
with the start codon of GST in pGEX-5X-1 and exhibits 4 point mutations. One out of the 4 point mutations is not conserved. In 2 
cases, UCA (Ser) has replaced UCC (Ser). In another case, UUG (Leu) has replaced CUG (Leu). For the non-conserved point 
mutation, *UAU (Tyr) has replaced CAU (His). Tyr is a hydrophobic amino acid while his is a basic amino acid. Despite one non-
conserved point mutation in the B30.2 domain of pGEX-5X-1-βB30.2, E. Coli BL21-pGEX-5X-1-βB30.2 was still used for protein 
purification (Section 3.10). 
 
BamHI cleavage site 
B30.2 Domain Vector Thrombin cleavage site Insert 
UCA UCA 
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3.9 BIOINFORMATICS ANALYSIS OF GST, GST-αB30.2 AND GST-βB30.2 
PROTEINS 
 
Bioinformatics analysis were carried out to predict the properties of GST, GST-
αB30.2 and GST-βB30.2 proteins that will be produced upon IPTG induction of the 
bacterial clones E. coli BL21-pGEX-5X-1, E. Coli BL21-pGEX-5X-1-αB30.2 and E. 
Coli BL21-pGEX-5X-1-βB30.2 respectively. The predicted properties of the fusion 
proteins such as isoelectric point and molecular weight are shown in the respective 
figures and may be employed in purification purposes. 
 













           ---------|---------|---------|---------|---------|---------| 
         1 atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt 60 
         1 M  S  P  I  L  G  Y  W  K  I  K  G  L  V  Q  P  T  R  L  L   20 
           ---------|---------|---------|---------|---------|---------| 
        61 ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa 120 
        21 L  E  Y  L  E  E  K  Y  E  E  H  L  Y  E  R  D  E  G  D  K   40 
           ---------|---------|---------|---------|---------|---------| 
       121 tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat 180 
        41 W  R  N  K  K  F  E  L  G  L  E  F  P  N  L  P  Y  Y  I  D   60 
           ---------|---------|---------|---------|---------|---------| 
       181 ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac 240 
        61 G  D  V  K  L  T  Q  S  M  A  I  I  R  Y  I  A  D  K  H  N   80 
           ---------|---------|---------|---------|---------|---------| 
       241 atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg 300 
        81 M  L  G  G  C  P  K  E  R  A  E  I  S  M  L  E  G  A  V  L   100 
           ---------|---------|---------|---------|---------|---------| 
       301 gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt 360 
       101 D  I  R  Y  G  V  S  R  I  A  Y  S  K  D  F  E  T  L  K  V   120 
           ---------|---------|---------|---------|---------|---------| 
       361 gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa 420 
       121 D  F  L  S  K  L  P  E  M  L  K  M  F  E  D  R  L  C  H  K   140 
           ---------|---------|---------|---------|---------|---------| 
       421 acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat 480 
       141 T  Y  L  N  G  D  H  V  T  H  P  D  F  M  L  Y  D  A  L  D   160 
           ---------|---------|---------|---------|---------|---------| 
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481 gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa 540 
       161 V  V  L  Y  M  D  P  M  C  L  D  A  F  P  K  L  V  C  F  K   180 
           ---------|---------|---------|---------|---------|---------| 
       541 aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca 600 
       181 K  R  I  E  A  I  P  Q  I  D  K  Y  L  K  S  S  K  Y  I  A   200 
           ---------|---------|---------|---------|---------|---------| 
       601 tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat 660 
       201 W  P  L  Q  G  W  Q  A  T  F  G  G  G  D  H  P  P  K  S  D   220 
           ---------|---------|---------|---------|---------|---------| 
       661 ctgatcgaaggtcgtgggatccccgaattcccgggtcgactcgagcggccgcatcgtgac 720 
       221 L  I  E  G  R  G  I  P  E  F  P  G  R  L  E  R  P  H  R  D   240 
           -------- 
       721 tgactgac 728 
       241 *  L     242 
 
 
Figure 31. PEPSTAT analysis of GST showing the predicted molecular weight, 
isoelectric point and other properties of the protein. 
PEPSTATS of GST from 1 to 240 
 
Molecular weight   = 28027.41    Residues = 240    
Average Residue Weight  = 116.781   Charge   = -0.5   
Isoelectric Point   = 6.4035 
Probability of expression in inclusion bodies = 0.529 
 
Residue  Number  Mole%  DayhoffStat 
A = Ala  10  4.167    0.484    
B = Asx  0  0.000    0.000    
C = Cys  4  1.667    0.575    
D = Asp  19  7.917    1.439    
E = Glu  19  7.917    1.319    
F = Phe  10  4.167    1.157    
G = Gly  17  7.083    0.843    
H = His  7  2.917    1.458    
I = Ile  15  6.250    1.389    
K = Lys  21  8.750    1.326    
L = Leu  29  12.083   1.633    
M = Met  9  3.750    2.206    
N = Asn  4  1.667    0.388    
P = Pro  16  6.667    1.282    
Q = Gln  5  2.083    0.534    
R = Arg  13  5.417    1.105    
S = Ser  9  3.750    0.536    
T = Thr  6  2.500    0.410    
V = Val  9  3.750    0.568    
W = Trp  4  1.667    1.282    
X = Xaa  0  0.000    0.000    
Y = Tyr  14  5.833    1.716    
Z = Glx  0  0.000    0.000  
   
Property Residues   Number  Mole% 
Tiny  (A+C+G+S+T)   46  19.167 
Small  (A+B+C+D+G+N+P+S+T+V)  94  39.167 
Aliphatic (I+L+V)    53  22.083 
Aromatic (F+H+W+Y)   35  14.583 
Non-polar (A+C+F+G+I+L+M+P+V+W+Y) 137  57.083 
Polar  (D+E+H+K+N+Q+R+S+T+Z)  103  42.917 
Charged  (B+D+E+H+K+R+Z)  79  32.917 
Basic  (H+K+R)    41  17.083 
Acidic  (B+D+E+Z)   38  15.833 
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Figure 32. PRETTYSEQ results showing nucleotide and amino acid sequence of 
GST-αB30.2. The thrombin cleavage site that separates that GST domain and the 
αB30.2 domain is underlined and the 5’-pGEX sequencing primer binding site is 
highlighted in blue. 
 
.
           ---------|---------|---------|---------|---------|---------| 
         1 atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt 60 
         1 M  S  P  I  L  G  Y  W  K  I  K  G  L  V  Q  P  T  R  L  L   20 
 
           ---------|---------|---------|---------|---------|---------| 
        61 ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa 120 
        21 L  E  Y  L  E  E  K  Y  E  E  H  L  Y  E  R  D  E  G  D  K   40 
 
           ---------|---------|---------|---------|---------|---------| 
       121 tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat 180 
        41 W  R  N  K  K  F  E  L  G  L  E  F  P  N  L  P  Y  Y  I  D   60 
 
           ---------|---------|---------|---------|---------|---------| 
       181 ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac 240 
        61 G  D  V  K  L  T  Q  S  M  A  I  I  R  Y  I  A  D  K  H  N   80 
 
           ---------|---------|---------|---------|---------|---------| 
       241 atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg 300 
        81 M  L  G  G  C  P  K  E  R  A  E  I  S  M  L  E  G  A  V  L   100 
 
           ---------|---------|---------|---------|---------|---------| 
       301 gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt 360 
       101 D  I  R  Y  G  V  S  R  I  A  Y  S  K  D  F  E  T  L  K  V   120 
 
           ---------|---------|---------|---------|---------|---------| 
       361 gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa 420 
       121 D  F  L  S  K  L  P  E  M  L  K  M  F  E  D  R  L  C  H  K   140 
 
           ---------|---------|---------|---------|---------|---------| 
       421 acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat 480 
       141 T  Y  L  N  G  D  H  V  T  H  P  D  F  M  L  Y  D  A  L  D   160 
 
           ---------|---------|---------|---------|---------|---------| 
       481 gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa 540 
       161 V  V  L  Y  M  D  P  M  C  L  D  A  F  P  K  L  V  C  F  K   180 
 
           ---------|---------|---------|---------|---------|---------| 
       541 aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca 600 
       181 K  R  I  E  A  I  P  Q  I  D  K  Y  L  K  S  S  K  Y  I  A   200 
 
           ---------|---------|---------|---------|---------|---------| 
       601 tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat 660 
       201 W  P  L  Q  G  W  Q  A  T  F  G  G  G  D  H  P  P  K  S  D   220 
 
           ---------|---------|---------|---------|---------|---------| 
       661 ctgatcgaaggtcgtgggatctcactggttccgcgtggatcttgtgacctcacctttgac 720 
       221 L  I  E  G  R  G  I  S  L  V  P  R  G  S  C  D  L  T  F  D   240 
 
           ---------|---------|---------|---------|---------|---------| 
       721 cgaaacaccataaacaactggatctctctttctgacaacgatacatttgcagcctctgag 780 
       241 R  N  T  I  N  N  W  I  S  L  S  D  N  D  T  F  A  A  S  E   260 
 
           ---------|---------|---------|---------|---------|---------| 
       781 catggaaaacggcagaactatccaaaacacccagaacgttttgttagttttaatcaggtg 840 








           ---------|---------|---------|---------|---------|---------| 
       841 ttgtgcaatgaggggctgatggggaaacattactgggaggtggagtggaacggatacatt 900 
       281 L  C  N  E  G  L  M  G  K  H  Y  W  E  V  E  W  N  G  Y  I   300 
 
           ---------|---------|---------|---------|---------|---------| 
       901 gatgtaggtattgcttacatttccatccccaggaaagaaattgactttgcgagtgctttc 960 
       301 D  V  G  I  A  Y  I  S  I  P  R  K  E  I  D  F  A  S  A  F   320 
 
           ---------|---------|---------|---------|---------|---------| 
       961 gggtacaatacctattcctgggttttaagctataatcccaaaattggatacatcgaaagg 1020 
       321 G  Y  N  T  Y  S  W  V  L  S  Y  N  P  K  I  G  Y  I  E  R   340 
 
           ---------|---------|---------|---------|---------|---------| 
      1021 cataaaaaaagagaatataatgtcagggcgcccaatccaggctttaaacgactaggactg 1080 
       341 H  K  K  R  E  Y  N  V  R  A  P  N  P  G  F  K  R  L  G  L   360 
 
           ---------|---------|---------|---------|---------|---------| 
      1081 tttctcgattggcgttatggcagtatatctttctatgctgtctcctctgatgaagtgcac 1140 
       361 F  L  D  W  R  Y  G  S  I  S  F  Y  A  V  S  S  D  E  V  H   380 
 
           ---------|---------|---------|---------|---------|---------| 
      1141 catcttcacaccttcaaaaccaaatttactgagcctgtttatccggccttcagtatcggg 1200 
       381 H  L  H  T  F  K  T  K  F  T  E  P  V  Y  P  A  F  S  I  G   400 
 
           ---------|---------|---------|---------|---------|- 
      1201 cctgccggtaaccacgatgtcgactcgagcggccgcatcgtgactgactga 1251 
       401 P  A  G  N  H  D  V  D  S  S  G  R  I  V  T  D  *   416 
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Figure 33. Pepstat analysis of GST-αB30.2 showing the predicted molecular weight, 
isoelectric point and other properties of the protein. 
 
PEPSTATS of GST-αB30.2 from 1 to 416 
 
Molecular weight   = 48203.91    Residues = 416    
Average Residue Weight   = 115.875   Charge   = 3.0    
Isoelectric Point   = 6.8822 
Improbability of expression in inclusion bodies = 0.663 
 
Residue  Number  Mole%  DayhoffStat 
A = Ala  19  4.567    0.531    
B = Asx  0  0.000    0.000    
C = Cys  6  1.442    0.497    
D = Asp  29  6.971    1.267    
E = Glu  27  6.490    1.082    
F = Phe  21  5.048    1.402    
G = Gly  30  7.212    0.859    
H = His  14  3.365    1.683    
I = Ile  27  6.490    1.442    
K = Lys  31  7.452    1.129    
L = Leu  38  9.135    1.234    
M = Met  10  2.404    1.414    
N = Asn  17  4.087    0.950    
P = Pro  23  5.529    1.063    
Q = Gln  7  1.683    0.431    
R = Arg  21  5.048    1.030    
S = Ser  26  6.250    0.893    
T = Thr  14  3.365    0.552    
V = Val  21  5.048    0.765    
W = Trp  9  2.163    1.664    
X = Xaa  0  0.000    0.000    
Y = Tyr  26  6.250    1.838    
Z = Glx  0  0.000    0.000    
 
Property Residues   Number  Mole% 
Tiny  (A+C+G+S+T)   95  22.837 
Small  (A+B+C+D+G+N+P+S+T+V)  185  44.471 
Aliphatic (I+L+V)    86  20.673 
Aromatic (F+H+W+Y)   70  16.827 
Non-polar (A+C+F+G+I+L+M+P+V+W+Y) 230  55.288 
Polar  (D+E+H+K+N+Q+R+S+T+Z)  186  44.712 
Charged  (B+D+E+H+K+R+Z)  122  29.327 
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Figure 34. PRETTYSEQ result showing nucleotide and amino acid sequence of GST-
βB30.2. The thrombin cleavage site that separates that GST domain and the βB30.2 
domain is underlined and the 5’-pGEX sequencing primer binding site is highlighted 
in blue. 
            ---------|---------|---------|---------|---------|---------|          1 atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt 60 
         1 M  S  P  I  L  G  Y  W  K  I  K  G  L  V  Q  P  T  R  L  L   20 
 
           ---------|---------|---------|---------|---------|---------| 
        61 ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa 120 
        21 L  E  Y  L  E  E  K  Y  E  E  H  L  Y  E  R  D  E  G  D  K   40 
 
           ---------|---------|---------|---------|---------|---------| 
       121 tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat 180 
        41 W  R  N  K  K  F  E  L  G  L  E  F  P  N  L  P  Y  Y  I  D   60 
 
           ---------|---------|---------|---------|---------|---------| 
       181 ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac 240 
        61 G  D  V  K  L  T  Q  S  M  A  I  I  R  Y  I  A  D  K  H  N   80 
 
           ---------|---------|---------|---------|---------|---------| 
       241 atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg 300 
        81 M  L  G  G  C  P  K  E  R  A  E  I  S  M  L  E  G  A  V  L   100 
 
           ---------|---------|---------|---------|---------|---------| 
       301 gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt 360 
       101 D  I  R  Y  G  V  S  R  I  A  Y  S  K  D  F  E  T  L  K  V   120 
 
           ---------|---------|---------|---------|---------|---------| 
       361 gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa 420 
       121 D  F  L  S  K  L  P  E  M  L  K  M  F  E  D  R  L  C  H  K   140 
 
           ---------|---------|---------|---------|---------|---------| 
       421 acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat 480 
       141 T  Y  L  N  G  D  H  V  T  H  P  D  F  M  L  Y  D  A  L  D   160 
 
           ---------|---------|---------|---------|---------|---------| 
       481 gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa 540 
       161 V  V  L  Y  M  D  P  M  C  L  D  A  F  P  K  L  V  C  F  K   180 
 
           ---------|---------|---------|---------|---------|---------| 
       541 aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca 600 
       181 K  R  I  E  A  I  P  Q  I  D  K  Y  L  K  S  S  K  Y  I  A   200 
 
           ---------|---------|---------|---------|---------|---------| 
       601 tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat 660 
       201 W  P  L  Q  G  W  Q  A  T  F  G  G  G  D  H  P  P  K  S  D   220 
 
           ---------|---------|---------|---------|---------|---------| 
       661 ctgatcgaaggtcgtgggatctcactggttccgcgtggatcttgtgagctcaccctggac 720 
       221 L  I  E  G  R  G  I  S  L  V  P  R  G  S  C  E  L  T  L  D   240 
 
           ---------|---------|---------|---------|---------|---------| 
       721 ccagaaacagcacaccaggtcctgactctgtccgagggcaacaaaaaggcagtttcaggg 780 
       241 P  E  T  A  H  Q  V  L  T  L  S  E  G  N  K  K  A  V  S  G   260 
 
           ---------|---------|---------|---------|---------|---------| 
       781 aatacgaagtcacccaccgatcacctagagaagttcagccactttcagcaggtgatgtgc 840 
       261 N  T  K  S  P  T  D  H  L  E  K  F  S  H  F  Q  Q  V  M  C   280 
 




           ---------|---------|---------|---------|---------|---------| 
       841 accaaggggctgagtgggcgccattactgggagttagagtggtctggttacgttggtgca 900 
       281 T  K  G  L  S  G  R  H  Y  W  E  L  E  W  S  G  Y  V  G  A   300 
 
           ---------|---------|---------|---------|---------|---------| 
       901 ggtgtcacatataaaggaatcggtaggaaaacatctacctcagattcctcccttggaaaa 960 
       301 G  V  T  Y  K  G  I  G  R  K  T  S  T  S  D  S  S  L  G  K   320 
 
           ---------|---------|---------|---------|---------|---------| 
       961 aatgagaagtcctggctttttgaatattctacaaaatcaggctaccaacaaattcataat 1020 
       321 N  E  K  S  W  L  F  E  Y  S  T  K  S  G  Y  Q  Q  I  H  N   340 
 
           ---------|---------|---------|---------|---------|---------| 
      1021 agtaaaaagactcgtgtcactgtgtcctccactggctttaaacttttaggagtgtatctg 1080 
       341 S  K  K  T  R  V  T  V  S  S  T  G  F  K  L  L  G  V  Y  L   360 
 
           ---------|---------|---------|---------|---------|---------| 
      1081 gactggcctgctggcactctgtccttctacatggtcaacaaagcctgggttactcatctc 1140 
       361 D  W  P  A  G  T  L  S  F  Y  M  V  N  K  A  W  V  T  H  L   380 
 
           ---------|---------|---------|---------|---------|---------| 
      1141 cacactttccacaccaaatttaatgaagctgtttatccagccttcttgattggggatgca 1200 
       381 H  T  F  H  T  K  F  N  E  A  V  Y  P  A  F  L  I  G  D  A   400 
 
           ---------|---------|---------|---------|---------|- 
      1201 caacagaaagtcaatgatgtcgactcgagcggccgcatcgtgactgactga 1251 
       401 Q  Q  K  V  N  D  V  D  S  S  G  R  I  V  T  D  *   416 
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Figure 35. Pepstat analysis of GST-βB30.2 showing the predicted molecular weight, 
isoelectric point and other properties of the protein.
PEPSTATS of GST-βB30.2 from 1 to 416 
 
Molecular weight   = 47452.20    Residues = 416    
Average Residue Weight   = 114.068  Charge   = 7.0    
Isoelectric Point   = 7.6474 
Improbability of expression in inclusion bodies = 0.692 
 
Residue  Number  Mole%  DayhoffStat 
A = Ala  18  4.327    0.503    
B = Asx  0  0.000    0.000    
C = Cys  6  1.442    0.497    
D = Asp  26  6.250    1.136    
E = Glu  26  6.250    1.042    
F = Phe  17  4.087    1.135    
G = Gly  33  7.933    0.944    
H = His  14  3.365    1.683    
I = Ile  19  4.567    1.015    
K = Lys  37  8.894    1.348    
L = Leu  44  10.577   1.429    
M = Met  11  2.644    1.555    
N = Asn  11  2.644    0.615    
P = Pro  18  4.327    0.832    
Q = Gln  12  2.885    0.740    
R = Arg  15  3.606    0.736    
S = Ser  30  7.212    1.030    
T = Thr  24  5.769    0.946    
V = Val  24  5.769    0.874    
W = Trp  9  2.163    1.664    
X = Xaa  0  0.000    0.000    
Y = Tyr  22  5.288    1.555    
Z = Glx  0  0.000    0.000    
 
Property Residues   Number  Mole% 
Tiny  (A+C+G+S+T)   111  26.683 
Small  (A+B+C+D+G+N+P+S+T+V)  190  45.673 
Aliphatic (I+L+V)    87  20.913 
Aromatic (F+H+W+Y)   62  14.904 
Non-polar (A+C+F+G+I+L+M+P+V+W+Y) 221  53.125 
Polar  (D+E+H+K+N+Q+R+S+T+Z)  195  46.875 
Charged  (B+D+E+H+K+R+Z) 118 28.365 
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Figure 36. Pepstat analysis of GST-βB30.2 (mutated – refer to section 3.8.2) showing 






















PEPSTATS of GST-βB30.2 1 from 1 to 416 
 
Molecular weight   = 47464.20    Residues = 416    
Average Residue Weight   = 114.097  Charge   = 6.5    
Isoelectric Point   = 7.6291 
Improbability of expression in inclusion bodies = 0.700 
 
Residue  Number  Mole%  DayhoffStat 
A = Ala  18  4.327    0.503    
B = Asx  0  0.000    0.000    
C = Cys  6  1.442    0.497    
D = Asp  26  6.250    1.136    
E = Glu  26  6.250    1.042    
F = Phe  17  4.087    1.135    
G = Gly  33  7.933    0.944    
H = His  13  3.125    1.562    
I = Ile  19  4.567    1.015    
K = Lys  37  8.894    1.348    
L = Leu  44  10.577   1.429    
M = Met  11  2.644    1.555    
N = Asn  11  2.644    0.615    
P = Pro  18  4.327    0.832    
Q = Gln  12  2.885    0.740    
R = Arg  15  3.606    0.736    
S = Ser  31  7.452    1.065    
T = Thr  23  5.529    0.906    
V = Val  24  5.769    0.874    
W = Trp  9  2.163    1.664    
X = Xaa  0  0.000    0.000    
Y = Tyr  23  5.529    1.626    
Z = Glx  0  0.000    0.000    
 
Property Residues   Number  Mole% 
Tiny  (A+C+G+S+T)   111  26.683 
Small  (A+B+C+D+G+N+P+S+T+V)  190  45.673 
Aliphatic (I+L+V)    87  20.913 
Aromatic (F+H+W+Y)   62  14.904 
Non-polar (A+C+F+G+I+L+M+P+V+W+Y) 222  53.365 
Polar  (D+E+H+K+N+Q+R+S+T+Z)  194  46.635 
Charged  (B+D+E+H+K+R+Z)  117  28.125 
Basic  (H+K+R)    65  15.625 
Acidic  (B+D+E+Z)   52  12.500 
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3.10 PURIFICATION OF GST, GST-αB30.2 AND GST-βB30.2 PROTEINS 
 
3.10.1 AFFINITY PURIFICATION OF SOLUBLE GST, GST-αB30.2 OR GST-
βB30.2 
 
Soluble GST-αB30.2 (~48kDa) and GST-βB30.2 (~47kDa) in bacterial supernatant 
produced under the conditions of protein expression described in Section 2.4.2.1 were 
co-purified with a 57kDa protein under the native conditions of protein purification 
described in Section 2.4.2.3 (Figure 37). The 57kDa protein was found to be GroEL 
through N-terminal sequencing. Pure GST (~28kDa) without GroEL was purified 
under the same conditions. The yield of soluble GST-αB30.2 (+ GroEL) and GST-
βB30.2 (+GroEL) purified from 1l bacterial culture is low, i.e. 0.2535mg and 
0.2571mg respectively. Conversely, the yield of affinity purified soluble GST is high, 
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Figure 37. Purification of soluble GST-αB30.2, GST-βB30.2 and GST: (a) GST-
αB30.2 (~48kDa) + GroEL (57kDa), (b) GST-βB30.2 (~47kDa) + GroEL (57kDa) 
and (c) GST (26kDa). Fractions (1, 2) collected from FPLC were analyzed by 12% 
SDS-PAGE. Note the conditions of bacterial growth, protein expression and non-
denaturing protein purification described in Sections 2.4.2.1 and 2.4.2.3. M represents 
Bio-Rad broad-range molecular weight marker. 
 
 
           (a) GST-αB30.2  (b) GST-βB30.2  (c) GST 
 
    M     1        2                   M     1       2          M      1    
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3.10.2 ATTEMPTED REMOVAL OF GRO-EL FROM SOLUBLE GST-αB30.2 
AND GST-βB30.2 USING AN ATP WASH BUFFER 
 
As an attempt to separate co-purifying GroEL from GST-αB30.2 and GST-βB30.2 
(refer to Section above), an additional ATP washing step was included into the 
purification process (see Section 2.4.2.4). GroEL has been postulated to function 
together with GroES in the presence of ATP to facilitate the correct folding of 
proteins and their subsequent release from the GroEL-GroES complex (Fenton & 
Horwich, 2003 and references therein). The inclusion of the ATP washing step 
resulted in the purification of pure GST-βB30.2 without GroEL (Figure 38). GST-












Chapter 3 Results 
 
153 
Figure 38. Attempted removal of GroEL from GST-αB30.2 and GST-βB30.2 using 
an ATP wash buffer. (a) Successful removal of GroEL (57kDa) from GST-βB30.2  
(~47kDa) and (b) copurification of GroEL (57kDa) with GST-αB30.2 (~48kDa). M 
represents Bio-Rad broad-range molecular weight marker. Fraction 1 collected from 
FPLC were analyzed by 12% SDS-PAGE. 
 
(a) GST-βB30.2   (b) GST-αB30.2   
 
    M         1                 M       1     
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3.10.3 ATTEMPTED REMOVAL OF GRO-EL FROM SOLUBLE GST-αB30.2 
USING AN ATP WASH BUFFER AND GRO-ES 
 
Since there have been reports of successful removal of contaminating GroEL from 
GST-fusion proteins using a combination of an ATP wash buffer and GroES (Thain 
et al., 1996, Vandenbroeck & Billiau, 1998), this method was used as a further 
attempt to remove GroEL from GST-αB30.2. However, contaminating GroEL was 
still co-purified with GST-αB30.2 (Figure 39). 
 
Figure 37. Attempted removal of GroEL from GST-αB30.2 using a combination of 
an ATP wash buffer and GroES. GroEL (57kDa) is still copurified with GST-αB30.2 
(~48kDa). M represents Bio-Rad broad-range molecular weight marker. Fraction 1 
collected from FPLC were analyzed by 12% SDS-PAGE. 
 
 
                                   GST-αB30.2 
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3.10.4 PURIFICATION OF GST-αB30.2 AND GST-βB30.2 FROM 
INCLUSION BODIES 
 
3.10.4.1 METHOD 1 
 
Pure GST-αB30.2 and GST-βB30.2 was purified without Gro-EL from inclusion 
bodies solubilized with N-lauroylsarcosine (Figure 40, refer to Section 2.4.2.6.1). The 
amount of GST-αB30.2 and GST-βB30.2 purified from the inclusion bodies (21.3 
and 18.9 mg/l bacterial culture respectively) was much higher compared to that 
purified from the bacterial supernatant (i.e. 0.254 and 0.257 mg/l bacterial culture 
respectively).  
 
Figure 40. Purification of GST-αB30.2 and GST-βB30.2 from inclusion bodies 
solubilized with N-lauroylsarcosine. (a) GST-αB30.2 (~48kDa) and (b) GST-βB30.2 
(~47kDa) purified from inclusion bodies. M represents Bio-Rad broad-range 
molecular weight marker. Fractions (1,2) collected from FPLC were analyzed by 12% 
SDS-PAGE. 
 
     M    1         2                     M     1        2         
    
200 
116.25 
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3.10.4.2 METHOD 2 
 
Inclusion bodies containing GST-αB30.2 or GST-βB30.2 were obtained and prepared 
as described in section 2.4.2.6.2. The inclusion bodies solubilized in urea were 
refolded and analysed by SDS-PAGE (Figure 41). Large amounts of pure GST-
αB30.2 and GST-βB30.2 were found to be in the inclusion bodies preparation. As 
determined by Bradford assay, the amount of GST-αB30.2 and GST-βB30.2 from 1 
liter of bacterial culture are 16 mg and 12.1 mg respectively. 
 
Figure 41. Solubilization and refolding of inclusion bodies containing recombinant 
GST-αB30.2 or GST-βB30.2. Inclusion bodies preparation obtained for GST-αB30.2 
(lane 1) and GST-βB30.2 (lane 2) purified according to the method described in 
section 2.2.4.6.2 M represents Bio-Rad broad-range molecular weight marker. 
 
 







    45 kDa 
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3.10.5 WESTERN BLOTTING: IMMUNORECOGNITION OF GST-αB30.2 
AND GST-βB30.2 BY POLYCLONAL ANTIBODIES DIRECTED AGAINST 
SNTX 
 
GST-αB30.2 (+ GroEL) and GST-βB30.2 (- GroEL) both purified from the bacterial 
supernatant (see Section 3.10.2) were recognized by polyclonal anti-SNTX antibodies 
obtained from rabbits subcutaneously injected with native SNTX (120µg) emulsified 
in complete Freund’s adjuvant. (Figure 42). In addition, pure GST-αB30.2 and GST-
βB30.2 purified from inclusion bodies (see Section 3.10.4.2 and Section 2.4.2.6.2) 
were also detectable by the polyclonal anti-SNTX antibodies (Figure 43). 
 
Figure 42. Immunodetection of SNTX and affinity purified GST-αB30.2 (+GroEL) 
and GST-βB30.2.  SNTX, GST-αB30.2 (+ GroEL) and GST-βB30.2 (- GroEL) were 
loaded into lane 1, 2 and 3 respectively.   
 
         1             2             3      
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Figure 43. Immunodetection of pure GST-αB30.2 and GST-βB30.2 purified from 
inclusion bodies preparation (see Section 3.10.4.2 and Section 2.2.4.6.2). Lane 1 in 
both (a) and (b) contains SNTX. Similarly lane 2 in (a) and (b) contains proteins 
purified from inclusion bodies. 
 
             (a) GST-αB30.2               (b) GST-βB30.2 
      1     2                       1      2      
 





Chapter 3 Results 
 
159 
3.11 ORGAN BATH STUDIES WITH PURIFIED RECOMBINANT 
PROTEINS 
 
Organ bath studies with cumulative concentrations of SNTX led to progressive 
vasorelaxation of 0.32µM PE-precontracted, 2mm thoracic rat aortic rings (Figure 
21). Using equimolar of GST-αB30.2 (+GroEL), GST-βB30.2 or GST-αB30.2 
(+GroEL) + GST-βB30.2 affinity purified according to Section 2.4.2.4  and Section 
3.10.2 from the soluble fraction of IPTG induced E. coli BL21 bacterial cells did not 
lead to the vasorelaxation of the PE-precontracted aortic rings. The use of equimolar 
of GST-αB30.2, GST-βB30.2 or GST-αB30.2 + GST-βB30.2 that was purified from 
N-lauroylsarcosine solubilized inclusion bodies also did not lead to the vasorelaxation 
of the PE-precontracted aortic rings. The use of control did not cause any 
vasorelaxation as well. These results suggest that the B30.2 domains in SNTX may 
not be responsible for the vasorelaxing effect of SNXT on precontracted rat aorta. 
The domains may possibly be involved in other biological effects of SNTX.  
 
 




























Stonustoxin (SNTX), a lethal protein factor isolated from the venom of the stonefish 
Synanceja horrida (Poh et al., 1991) causes a number of biological activities including 
species-specific haemolysis and platelet aggregation, edema-induction, hypotension, 
endothelium-dependent vasorelaxation, and inhibition of neuromuscular function in the 
mouse hemidiaphragm and chick biventer cervicis muscle (Low et al., 1993; Khoo et al., 
1995; Chen et al., 1997; Sung et al., 2002). Lethality arising from SNTX is due to the 
marked hypotension that results from the potent vasorelaxation it causes (Low et al., 
1993).  
 
The focus of this thesis is to find out the potential involvement of hydrogen sulfide (H2S) 
acting in synergy with nitric oxide (NO) in SNTX-induced vasorelaxation of 
endothelium-intact, precontracted rat thoracic aortic rings. H2S is a novel endogenous 
smooth muscle relaxant discovered by Hosoki et al., 1997. As SNTX causes 
vasorelaxation, H2S could possibly be a gaseous mediator of SNTX’s vasorelaxing effect. 
In addition, H2S may also possibly work with NO in causing vasorelaxation. Low et al., 
1993 through the use of inhibitors in organ bath studies found that NO is a component of 
SNTX-induced vasorelaxation of endothelium-intact, precontracted rat aorta.  
 
The other aim of this thesis is to find out whether if the B30.2 domains present in each of 
the SNTX subunit possess any vasorelaxing effects. The B30.2 domain is present in a 
rapidly growing family of proteins with diverse functions and cellular locations (refer to 
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Section 1.2.6.4). Currently not much is known about the function and structure of this 
domain. An attempt was made to express the SNTX B30.2 domains as a fusion with 
Glutathione S-Transferase (GST) in E. coli for subsequent purification and functional 
studies.   
 
4.1 PURIFICATION OF SNTX FOR PHARMACOLOGICAL STUDIES 
 
As a first step to the series of experiments to be done, SNTX was purified from S. 
horrida venom using Sephacryl S-200 High Resolution (HR) gel filtration 
chromatography and DEAE Bio-Gel A anion exchange chromatography, according to the 
method of Poh et al., 1991 with some modifications. A decrease in total purification time 
resulted from a change to the column size and flow rate used for DEAE Bio-Gel A anion 
exchange chromatography. Using the method described in Section 2.4.1.3, anion-
exchange chromatography took 1 day compared to 4 days when the method described for 
Poh et al., 1991 for this part of the purification was used.  
 
The purification was able to yield a protein that is made up of two subunits (71 and 
79kDa) linked via non-disulfide bonds (Section 3.1.3). SNTX has been shown to have a 
molecular weight of 148kDa and is made up of two subunits SNTX-α and SNTX-β with 
molecular weights of 71 and 79kDa respectively (Poh et al., 1991). The subunits have 
been shown to be linked via non-disulfide linkages (Ghadessey et al., 1996). To confirm 
that the purified protein described in Section 3.1.3 was indeed SNTX, organ bath studies 
with endothelium-intact, 0.32µM L-phenylephrine-precontracted, 2mm rat thoracic aortic 
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rings was done to check whether if the protein possesses any vasorelaxation effects (see 
Section 3.3). Stonustoxin has been found to cause vasorelaxation of endothelium-intact, 
precontracted rat aorta or rat thoracic aortic rings by previous studies in our laboratory 
(Low et al., 1993; Sung et al., 2002).  
 
4.2 PRELIMINARY ORGAN BATH STUDIES 
 
Low et al., 1993 demonstrated that SNTX (20-160ng/ml) causes vasorelaxation of 
endothelium-intact rat aortic strips (from the descending aortae) precontracted with 25nM 
noradrenaline (NA). Sung et al., 2002 also demonstrated that progressive addition of 
SNTX (5-640ng/ml) causes cumulative vasorelaxation of 4mm, endothelium-intact rat 
thoracic aortic rings precontracted with 7.5 X 10-5 M L-phenylephrine hydrochloride 
(PE). In my experiments, 2mm rat thoracic aortic rings were used and preliminary 
experiments were done to check their response to PE and acetylcholine chloride (Ach). 
2mm aortic rings were used instead of aortic strips and 4mm aortic rings so that more 
experiments can be conducted with one strip of thoracic aortae, and comparisons can be 
made for different drug treatment on sections of one thoracic aortae. 
 
4.2.1 Effect of L-phenylephrine Hydrochloride on 2mm Rat Thoracic Aortic Rings 
 
PE like NA used by Low et al., 1993 causes vasoconstriction by binding to alpha 1-
adrenoceptors on vascular smooth muscle (Rang et al., 1994). This binding lead to the 
activation of the polyphosphoinositide cascade which leads to the sequestration of Ca2+ 
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from intracellular stores; as well as the influx of Ca2+ through nifedipine-sensitive Ca2+ 
channels to mediate the contraction of vascular smooth muscle (Nishimura et al., 1991). 
However, PE unlike NA is not a catechol derivative that is inactivated by Catechol-O-
methyltransferase (COMT).  As PE is not readily broken down, it produces a more easily 
monitored, stable contractile response of the aorta than NA. The vasorelaxant effect 
produced by SNTX on PE-precontracted aortic rings should also theoretically show less 
variation than NA-precontracted aortic rings and hence were used in my experiments. 
The results obtained from the cumulative addition of PE to 2mm rat thoracic aortic rings 
showed progressive vasoconstriction of the aortic rings, with a cumulative dose-
vasoconstriction curve with an IC50 of 0.0390 µM and an EC85 of 0.32µM. 0.32µM PE 
was used to precontract 2mm rat thoracic aortic rings prior to any vasorelaxation 
experiments.  
 
4.2.2 Effect of Acetylcholine Chloride on 2mm Rat Thoracic Aortic Rings 
 
Before using an aortic ring for experimentation, it was tested with 0.32µM PE to check 
for the response of its vascular smooth muscle. In addition, it was also tested with Ach to 
check for the integrity and the responsiveness of its single layer of endothelial cells, to 
check whether if it has been denuded during the isolation and processing of the thoracic 
aortae. Ach acts on muscarinic M3 receptors on the endothelium to cause the release of 
nitric oxide, which diffuses to the vascular smooth muscle to activate guanylyl cyclase, 
cause an increase in cGMP and the subsequent vasorelaxation of the vascular smooth 
muscle (Furchgott & Zawadzki, 1980). To determine the concentration of Ach to use to 
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test for the integrity and responsiveness of the endothelial cells, 0.32µM PE-
precontracted aortic rings were tested with cumulative amounts of Ach. The results 
showed that cumulative addition of Ach to 0.32µM PE-precontracted aortic rings led to 
progressive vasorelaxation with IC50 of 0.0824uM and EC85 of 2.56µM. 2.56µM Ach 
corresponding to EC85 was used to check for the integrity of the endothelial cells. 
0.32µM PE-precontracted aortic rings that exhibit greater or equal to 70% vasorelaxation 
with 2.56µM Ach (refer to Figure 14) were termed as endothelium-intact aortic rings and 
were used for further experimentation, with SNTX or purified B30.2 recombinant 
proteins.  
 
4.3 VASORELAXATION BY SNTX  
 
To confirm that the purified protein described in Section 4.1 was indeed SNTX, it was 
added cumulatively to 2mm, endothelium-intact, 0.32µM PE-precontracted rat thoracic 
aortic rings in organ bath studies to check whether if it causes vasorelaxation (Section 
3.3). The protein progressively causes vasorelaxation of the aortic rings. In addition, the 
vasorelaxation was inhibited by L-NAME which indicates a role of nitric oxide (NO) as a 
mediator of SNTX’s effects. This is consistent with what has been determined by Low et 
al., 1993 and Julia et al., 2002, that NO is responsible for SNTX-induced vasorelaxation 
of precontracted aorta or aortic rings. Together with the PAGE studies, the organ bath 
studies confirmed that the purified protein in Section 3.1.3 was SNTX. The purified 
SNTX was used for further tests in inhibitor studies to check for other mediators of 
SNTX’s vasorelaxing effect. 
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4.4 INVOLVEMENT OF HYDROGEN SULFIDE (H2S) ON SNTX-INDUCED 
VASORELAXATION 
 
Gases such as nitric oxide (NO) and carbon monoxide play important roles in both 
normal physiology and in disease. In recent years, efforts have been directed towards 
detecting the endogenous biological production of other naturally occurring gases such as 
hydrogen sulfide (H2S), and elucidating their potential physiological roles.  
 
In 1997, H2S which is a well known toxic gas associated with many industrial fatalities 
(Burnett et al., 1977; Guidotti, 1994; Synder et al., 1995), was found to be an 
endogenously generated smooth muscle relaxant that may work in synergy with NO 
(Hosoki et al., 1997). As the stonefish toxin of interest SNTX relaxes precontracted aorta 
(Low et al., 1993 and Sung et al., 2002), H2S could possibly be a mediator of SNTX’s 
vasorelaxing effect beside NO. NO is a well-known smooth muscle relaxant (Furchgott et 
al., 1980; Ignarro et al., 1984; Palmer et al., 1987 and 1988) and has been determined by 
Low et al., 1993 and Sung et al., 2002 to play a part in SNTX-induced vasorelaxation of 
precontracted rat aorta. Hence, a series of RT-PCR and organ bath studies were 
conducted to investigate the role of H2S in SNTX-induced vasorelaxation of 
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4.4.1 RT-PCR DETECTION OF CSE BUT NOT CBS IN RAT’S THORACIC AORTA 
 
To date, CSE is the only H2S-generating enzyme that has been identified in vascular 
tissues (Hosoki et al., 1997; Zhao et al., 2001). Northern blot hybridization using a 
BamHI fragment of CSE cDNA (from Erickson et al., 1990) showed that CSE is present 
in rat’s thoracic aorta and portal vein (Hosoki et al., 1997). With an Eco RI fragment of 
CBS (from Swaroop et al., 1992), CBS was not detected in the same vascular tissues 
(Hosoki et al., 1997). Subsequently, Zhao et al., 2001 cloned and sequenced the CSE 
isoform in rat mesenteric artery (Pubmed ID: AB052882) and other vascular tissues 
(Pubmed ID: AY032872).  
 
Preliminarily to using CSE inhibitors for organ bath studies to see their effect on SNTX-
induced vasorelaxation of PE-precontracted thoracic aortic rings, reverse-transcription 
polymerase chain reaction i.e. RT-PCR was conducted and the results showed that CSE 
but not CBS was detected in the thoracic aorta of Sprague Dawley rats.  
 
4.4.2 INHIBITION OF SNTX-INDUCED VASORELAXATION BY CSE-
INHIBITORS 
 
Cystathionine γ-lyase (CSE) mRNA expression and H2S production have been detected 
in the thoracic aorta (Hosoki et al, 1997). To determine if H2S, a novel endogenous 
gasotransmitter is involved in vasorelaxation by Stonustoxin, D, L-proparglyglycine 
(PAG) and β-cyano-L-alanine (BCA) were used in organ bath studies to see if 
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vasorelaxation of 0.32µM PE-precontracted rat aortic rings by Stonustoxin is inhibited. 
PAG is an irreversible inhibitor of CSE (IC50 = 10-4M, Stipanuk et al., 1982; Uren et al., 
1978) while BCA, a structural analogue of PAG, is a competitive inhibitor of CSE (IC50 
= 10-5M, Uren et al., 1978; Pfeffer, 1967).  
 
The results obtained indicate that H2S could be a gaseous mediator of SNTX’s 
vasorelaxing effect. Preincubation of 2mm, endothelium-intact, 0.32µM PE-
precontracted thoracic aortic rings with 1mM PAG or 1mM BCA for 1h prior to SNTX 
vasorelaxation of PE-precontracted aortic tissues resulted in an inhibition of the 
vasorelaxant effect of SNTX, with an increase in the IC50 of SNTX and a decrease in 
maximum vasorelaxation induced by SNTX (Figure 24).  
 
4.5 SYNERGISTIC EFFECT OF HYDROGEN SULFIDE (H2S) AND NITRIC 
OXIDE (NO) ON VASORELAXATION BY SNTX 
 
Since H2S is possibly a mediator of SNTX’s vasorelaxing effect, we would like to see 
whether does it work together with NO to bring about vasorelaxation. Previous 
experiments in our laboratory has showed that NO is responsible for SNTX-induced 
vasorelaxation of rat aorta or aortic rings (Low et al., 1997; Sung et al., 2002). In 
addition, Hosoki et al., 1997 showed that H2S acts in synergy to bring about smooth 
muscle (such as the thoracic aorta) vasorelaxation. A combination of CSE-inhibitor and 
nitric oxide synthase inhibitor was used in organ bath studies and the results showed that 
preincubation of the aortic rings with L-NAME in conjuction with PAG or BCA led to an 
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inhibition of SNTX-induced vasorelaxation (Section 3.6). The inhibitory effect is much 
greater than when each inhibitor is used individually and hence suggests that H2S and NO 
work together to bring about SNTX-mediated vasorelaxation of precontracted aortic 
rings. 
 
4.6 EFFECT OF L-CYSTEINE ON THORACIC AORTIC RINGS 
 
Teague et al., 2001 showed that 1mM L-Cysteine was able to cause a slowly developing 
decline in the size of BCA-augmented twitch response of guinea pig ileum. Cheng et al., 
2004 also showed that 1mM L-cysteine increased endogenous H2S production by 6-fold 
in rat mesenteric artery tissues and decreased contractility of mesenteric artery beds. As a 
result, 1mM L-cysteine was used to see whether the inhibition by BCA on SNTX-
induced vasorelaxation of 2mm, endothelium-intact, 0.32µM PE-precontracted thoracic 
aortic rings was reversed. However, when 1mM L-Cysteine was added to endothelium-
intact, resting thoracic aortic rings preincubated for 30mins with BCA or control saline, a 
transient increase in tone of the thoracic aortic rings was observed in all cases (Figure 
26). The transient increase in tone of the thoracic aortic rings caused by L-cysteine is 
unexpected and cannot be explained by pH changes as Krebs solution is an effective 
buffer. Currently, this observation by L-cysteine has not been reported in the literature. 
Theoretically speaking, L-cysteine is a substrate for H2S biosynthesis and since H2S 
causes vasorelaxation, this phenomenon should not be observed. Further work with 
regards to the effect of L-cysteine and cystine on vascular tone could possibly be done. 
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4.7 FUNCTIONAL DOMAINS INVOLVED IN SNTX-INDUCED 
VASORELAXATION  
 
4.7.1 THE B30.2 DOMAIN OF SNTX-α AND SNTX-β 
(Bacterial clones confirmation, Bioinformatics Analysis and Purification) 
 
The cDNA of SNTX-α  and SNTX-β, the two subunits that make up SNTX have been 
isolated, characterized and cloned from a Synanceja horrida venom gland cDNA library 
(Ghadessey et al., 1996). SNTX shows no significant homology to other proteins except 
that it possess a small stretch of amino acids (in each of its subunit) that make up a B30.2 
domain that is present in a rapidly growing family of proteins with diverse functions and 
cellular locations (Henry et al., 1998). Currently, there is little information regarding the 
function of the B30.2 domain, except that it was shown that the B30.2 domain in mouse 
butyrophilin is able to interact with xanthine oxidase of mammary epithelial cells and 
milk fat globule membrane (Ishii et al., 1995). The structure of a protein with this domain 
has also not been solved. Hence, in this project, we hope to produce the B30.2 domain in 
SNTX for functional and crystallographic studies. In particular, we would like to see 
whether the domains are responsible for SNTX-induced vasorelaxation.  
 
4.7.1.1 BACTERIAL CLONES CONFIRMATION  
 
The B30.2 domain in each of the α- and β- subunits of SNTX have been amplified by 
PCR and cloned into various bacterial expression systems (Sung, 2001; Chapter 3). The 
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use of bacterial cells offers certain advantages such as simplicity, short generation times, 
and large yields of products with low costs. More importantly, functional SNTX-subunits 
and domains could possibly be produced in prokaryotic expression systems because the 
venom-secreting cells of S. horrida that secretes SNTX were found to be different from 
other venom-secreting cells in scorpions, spiders and snakes in that they do not possess 
the features of a typical eukaryotic protein secreting cell (Gopalakrishnakone and Gwee, 
1993). The venom-secreting cells do not possess golgi apparatus nor rough endoplasmic 
reticulum. In addition, Ghadessey et al. (1996) also found that SNTX lack typical leader 
sequences and post-translational modifications that are characteristics of eukaryotic 
secretary proteins associated with the endoplasmic reticulum-golgi apparatus. These 
findings suggest that SNTX can be cloned into prokaryotes that do not possess the 
membranous organelles required for post-transcriptional and translational modifications.  
 
In my experiments, I used the bacterial clones E. coli BL21-pGEX-5X-1-αB30.2 and E. 
coli BL21-pGEX-5X-1-βB30.2 for the purification of GST-αB30.2 and GST-βB30.2 
proteins respectively. E. coli BL21-pGEX-5X-1 was used for the purification of control 
GST. Before purifying recombinant GST-αB30.2 and GST-βB30.2 fusion proteins for 
functional studies, PCR amplification and DNA sequencing were done to confirm that the 
B30.2 domains of SNTX-α and SNTX-β have been cloned-in-frame into E. coli BL21-
pGEX-5X-1-αB30.2 and E. coli BL21-pGEX-5X-1-βB30.2 respectively and that no 
mutations of the clones had occurred. PCR amplification of the B30.2 domains in the 
clones produced PCR products of the appropriate size. DNA sequencing of the amplified 
PCR products showed that the B30.2 domains had been cloned in frame, at the correct 
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orientation. No mutation of E. coli BL21-pGEX-5X-1-αB30.2 had occurred. However, E. 
coli BL21-pGEX-5X-1-βB30.2 showed 4 point mutations. 3 are conserved mutations 
where the amino acid encoded by the codon is not changed. The other mutation CAT 
(His) was replaced by TAT (Tyr). Tyr is hydrophobic whereas His is basic. However, the 
clone was still used for purification of GST-βB30.2. 
 
4.7.1.2 AFFINITY PURIFICATION OF SOLUBLE GST, GST-αB30.2 OR GST-
βB30.2 
 
Sung (2001) found that GST-αB30.2 and GST-βB30.2 were expressed both in the 
soluble fraction and as insoluble protein aggregates known as inclusion bodies within the 
cytoplasm of E. coli BL21-pGEX-5X-1-αB30.2 and E. coli BL21-pGEX-5X-1-βB30.2 
respectively during bacterial induction with IPTG. Affinity purification of GST-αB30.2 
and GST-βB30.2 from the soluble fraction of IPTG induced bacterial cells using a 5ml 
GSTrapFF column resulted in the purification of the fusion proteins together with a 
bacterial chaperonin GroEL. This is consistent with the results obtained by Sung JML. 
Affinity purification of GST using the same method as GST-αB30.2 and GST-βB30.2 
resulted in large amounts of pure GST, i.e. 27mg/l bacterial culture in comparison with 
the low quantities of GST-αB30.2 (+ GroEL) and GST-βB30.2 (+ GroEL), i.e. 0.254 and 
0.257mg/l bacterial culture respectively that was purified. 
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4.7.1.3 ATTEMPTED REMOVAL OF GRO-EL FROM SOLUBLE GST-αB30.2 AND 
GST-βB30.2 
 
GroEL is a tetradecamer of identical 57 kDa subunits, arranged in two heptameric rings 
stacked back-to-back with a central cavity in each ring (Fenton & Horwich, 2003). Each 
subunit comprises three domains: equatorial which binds ADP or ATP and provides the 
inter-ring contacts that hold the rings together; apical which contains the hydrophobic 
surface at the entrance to the cavity that binds non-native polypeptides and interacts with 
the co-chaperonin, GroES; and intermediate, which links the other domains together and 
has flexible hinges at each end that permit the large-scale domain movements that occur 
during a folding cycle in which non-native polypeptides are aided to fold correctly into 
their correct conformations. GroES, a co-chaperonin, is a single-ring heptamer of 
identical 10 kDa subunits that binds to GroEL in the presence of ADP or ATP, capping 
one cavity to form an asymmetric complex. GroES is dynamic during the reaction cycle, 
binding to and releasing from one GroEL ring and then the other.  
 
Since GroEL has been postulated to function together with GroES in the presence of ATP 
to aid in the proper folding of proteins into their native, functional conformation and their 
subsequent release from the GroEL-Gro-ES machinery (Fenton & Horwich, 2003 and 
references therein) and successful removal of GroEL from GST fusion proteins using an 
ATP wash buffer during purification has been reported (Thain et al., 1996), an ATP 
washing step was included into the purification of soluble GST-αB30.2 and GST-
βB30.2. The use of the ATP wash buffer resulted in the successful removal of 
Chapter 4 Discussion 
174 
contaminating GroEL from GST-βB30.2 but not GST-αB30.2. As a further attempt to 
purify pure GST-αB30.2 for functional studies, GroES was added to the ATP wash 
buffer and the buffer was applied to the GSTrapFF column in which GST-αB30.2 was 
bound. This did not help in removing GroEL form GST-αB30.2 which possibly indicates 
a different mechanism (i.e. kinetics and strength) of interaction between the GroEL-
GroES machinery and GST-αB30.2. As GST-αB30.2 could still be purified using a 
GSTrapFF column, this suggests that the GST part of GST-αB30.2 is possibly not 
enclosed within the chaperonin molecule and can interact with glutathione in the 
GSTrapFF column. Interaction of GroEL with GST-αB30.2 is thus possibly at the B30.2 
domain. The purification results obtained is generally similar to that obtained by Sung, 
2001. 
 
4.7.1.4 PURIFICATION OF GST-αB30.2 AND GST-βB30.2 FROM INCLUSION 
BODIES 
 
High level protein biosynthesis in prokaryotes may lead to the accumulation of rapidly 
synthesized heterologous proteins as light-refractile aggregates known as inclusion 
bodies. The extent of intracellular protein aggregation depends on the protein itself, the E. 
Coli strain, the rate of protein synthesis and the growth conditions. If the protein of 
interest could be refolded adequately so that biological activity can be obtained, the 
formation of inclusion bodies is desirable because proteolysis decreases, and purification 
can be facilitated. When the protein cannot be refolded from inclusion bodies, it must be 
produced in soluble form, which may not be so simple to achieve in E. coli.  
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Sung (2001) reported that GST-αB30.2 and GST-βB30.2 were expressed as inclusion 
bodies, i.e. insoluble protein aggregates in the cytoplasm of E. coli BL21-pGEX-5X-1-
αB30.2 and E. coli BL21-pGEX-5X-1-βB30.2 despite using a low bacterial growth 
temperature of 30°C and a low IPTG concentration of 0.1mM. Therefore, an attempt was 
made to purify more GST-αB30.2 and GST-βB30.2 proteins for pharmacological 
experiments from the inclusion bodies, in particular to verify whether they have any 
vasorelaxing effect on precontracted aorta. In addition, if more GST-αB30.2 and GST-
βB30.2 fusion proteins are purified, they can be used to screen for other biological 
activities that SNTX possesses. 
 
Solubilization of inclusion bodies with N-lauroylsarcosine or urea and their subsequent 
purification was done. Large amounts of pure GST-αB30.2 and GST-βB30.2 without the 
GroEL contaminant was obtained from the inclusion bodies as compared to the low 
amounts of GST-αB30.2 (+ GroEL) and GST-βB30.2 (+ GroEL) purified from the 
soluble fraction. Purification of GST-αB30.2 and GST-βB30.2 (for functional and 
structural studies) from inclusion bodies rather than from the soluble fraction could 
therefore be a better alternative as large amounts of pure recombinant fusion proteins 
could be obtained. However, the protein has to be tested to be functionally active as they 
could be denatured by the detergents and may not be properly refolded into their 
functional conformation. This aside, bioinformatics analysis in Section 3.9 to predict the 
properties of the recombinant proteins were done and may be incorporated in the 
purification of the recombinant fusion proteins. 
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4.7.1.5 IMMUNOLOGICAL DETECTION OF GST-αB30.2 AND GST-βB30.2 BY 
POLYCLONAL ANTI-SNTX ANTIBODIES 
 
Soluble GST-αB30.2 (+ Gro EL) and GST-βB30.2 purified from the cytoplasm of IPTG 
induced bacterial cells E. coli BL21-pGEX-5X-1-αB30.2 and E. coli BL21-pGEX-5X-1-
βB30.2 respectively by affinity chromatography was detected by polyclonal anti-SNTX 
antibodies obtained from rabbits by the subcutaneous injection of native SNTX (120µg) 
emulsified in complete Freund’s adjuvant. Pure GST-αB30.2 and GST-βB30.2 from 
urea-solubilized inclusion bodies of E. coli BL21-pGEX-5X-1-αB30.2 and E. coli BL21-
pGEX-5X-1-βB30.2 were also similarly detected by the polyclonal anti-SNTX 
antibodies. Previously, SNTX subunits had also been expressed in E. coli as cleavable 
maltose-binding fusion proteins that cross-react with antibodies raised against the native 
toxin (Ghadessey et al., 1996). The B30.2 domains can possibly be used as immunogen 
to produce antibodies to counteract the particular biological effect(s) that it produces. 
 
4.7.1.6 ORGAN BATH STUDIES 
 
Organ bath studies with cumulative concentrations of SNTX led to progressive 
vasorelaxation of 2mm, endothelium-intact, 0.32µM PE-precontracted rat thoracic aortic 
rings. Equimolar of GST-αB30.2 (+GroEL), GST-βB30.2 or GST-αB30.2 (+GroEL) + 
GST-βB30.2 affinity purified according to Section 2.4.2.4 from the soluble fraction of 
IPTG induced E. coli BL21 bacterial clones did not lead to the vasorelaxation of the 
precontracted aortic rings. Similarly, control GST purified under the same conditions also 
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did not possess any vasorelaxing effect. This could mean that the B30.2 domains in 
SNTX do not possess vasorelaxing effects. However, this may not be the case since 
successful purification of the B30.2 domains without the GST domain and GroEL have 
not been done. Cleavage of the GST domain from the B30.2 domain and subsequent 
B30.2 domain purification is not possible and detectable because of the low yield of 
starting fusion proteins purified under non-denaturing conditions. 
 
The use of equimolar of GST-αB30.2, GST-βB30.2 or GST-αB30.2 + GST-βB30.2 that 
was purified from N-lauroylsarcosine solubilized inclusion bodies also did not lead to 
vasorelaxation of the PE-precontracted thoracic aortic rings. Control GST was also 
unable to elicit any vasorelaxing effects. This indicates that the B30.2 domains of SNTX-
α and SNTX-β are possibly not involved in SNTX-induced vasorelaxation of 
precontracted aortic rings. However, since the fusion proteins are purified in the presence 
of detergents, they may have been denatured and not refolded into their functionally 
active conformation.  
 
In conclusion, if the SNTX B30.2 domains are not involved in the vasorelaxing 
properties of SNTX, it may possibly be involved in other biological effects of SNTX. 
Presently, SNTX has been shown to cause species-specific haemolysis and platelet 
aggregation, edema-induction, hypotension, endothelium-dependent vasorelaxation, and 
inhibition of neuromuscular function in the mouse hemidiaphragm and chick biventer 
cervicis muscle (Low et al., 1993; Khoo et al., 1995; Chen et al., 1997; Sung et al., 
2002). However, the use of more suitable protein expression systems may need to be 
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considered to obtain better protein yield. The use of eukaryotic expression systems may 
also be considered because even though it was reported that the venom-secreting cells of 
S. horrida do not have the typical features of a eukaryotic protein-secreting cell such as 
Golgi apparatus and rough endoplasmic reticulum (Gopalakrishnakone and Gwee, 1993), 
they do possess cisternae and secretory vacuoles. Currently, not many studies have been 
done to elucidate the halocrine mechanism of protein secretion exhibited by cells such as 
the venom-secreting cells of S. horrida. 
 
 




























Stonustoxin (SNTX), a 148kDa, dimeric protein from the stonefish Synanceja horrida 
was successfully purified according to the method of Poh et al. (1991) with some 
minor changes to the anion-exchange chromatography part of the purification 
process, leading to a decrease in the purification time. SNTX (10-640ng/ml) lead to 
vasorelaxation of 2mm, endothelium-intact, 0.32µM L-phenylephrine-precontracted 
rat thoracic aortic rings. The use of inhibitors in organ bath studies showed that 
hydrogen sulfide (H2S) is a gaseous mediator of SNTX’s effect and that it work 
together with nitric oxide (NO) to bring about vasorelaxation. In addition, an 
unexpected transient increase in tone of resting thoracic aortic rings was observed 
with 1mM L-cysteine.   
 
SNTX possesses a B30.2 domain in each of its subunit SNTX-α and SNTX-β. 
Expression of GST-αB30.2 and GST-βB30.2 fusion proteins using the bacterial 
clones E. coli-BL21-pGEX-5X-1-αB30.2 or E. coli-BL21-pGEX-5X-1-βB30.2 at a 
low culturing temperature of 30°C and a low IPTG concentration of 0.1mM was 
unable to prevent the aggregation of the fusion proteins as inclusion bodies. Low 
yields of GST-αB30.2 and GST-βB30.2 was copurified with a bacterial chaperonin 
GroEL from fusion proteins expressed and distributed in the soluble fraction. The 
inclusion of an ATP wash buffer into the purification process as an attempt to 
facilitate the refolding and subsequent release of the fusion proteins from the GroEL-
GroES complex was effective only for GST-βB30.2 but not GST-αB30.2. With the 
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use of an ATP wash buffer together with GroES, GroEl was still not removed from 
GST-αB30.2. The fusion proteins were used in organ bath studies on precontracted 
aortic rings. Equimolar SNTX concentrations of the fusion proteins and control GST 
was unable to elicit vasorelaxation indicating that the B30.2 domains in SNTX may 
not be responsible for SNTX’s vasorelaxing effects. However, this may not be very 
conclusive. For the case of GST-αB30.2, it is not removed from GroEL. Since GroEL 
has been found to be a bulky tetradecamer (Fenton & Horwich, 2003; refer to Section 
4.7.1.3), the B30.2 domain of GST-αB30.2 may be stearically hindered and unable to 
produce any biological effects. For the case of GST-βB30.2, it possesses a non-
conserved point mutation where CAT (His) was replaced by TAT (Tyr). Tyr is 
hydrophobic whereas His is basic. The point mutation may have affected any 
vasorelaxing function that the βB30.2 possesses. Otherwise, the GST portion may 
have affected its functional activity. The low yield of fusion proteins obtained under 
native, non-denaturing conditions was unable to allow the enzymatic cleavage of the 
βB30.2 domain from the GST portion and its subsequent purification and detection. 
Since GST-αB30.2 and GST-βB30.2 were expressed in majority as inclusion bodies, 
an attempt to purifiy the fusion proteins after solubilization with N-lauroylsarcosine 
was made. A high yield of pure GST-αB30.2 and GST-βB30.2 was obtained. 
However, equimolar SNTX concentrations of the fusion proteins were unable to elicit 
any vasorelaxing effects. A combination of equimolar SNTX concentrations of GST-
αB30.2 + GST-βB30.2 was also unable to elicit any vasorelaxing effect similarly to 
the GST control. This implies that the B30.2 domains in SNTX may not be 
responsible for its vasorelaxing effect. As SNTX is a relatively large molecule of 
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148kDa, the active moiety leading to SNTX-induced vasorelaxation of precontracted 
aorta may reside at another site instead of the B30.2 domain. Otherwise, if the B30.2 
domain is the functionally active moiety, it may need to be expressed in more suitable 
expression systems such as eukaryotic expression systems before it can be 
conformationally correct to elicit its biological activity. The change of protein 
expression systems to obtain higher yields of fusion proteins to study the effect of the 
B30.2 domains on other biological effects that SNTX possesses may also be 
interesting.   
 




























Hydrogen sulfide (H2S) was found to work in synergy with nitric oxide (NO) to mediate 
SNTX-induced vasorelaxation of rat thoracic aortic rings. This conjecture was based on 
the use of Cystathionine-γ-lyase (CSE) inhibitors (D, L-proparglyglycine and β-cyano-L-
alanine) in organ bath studies. In future, the measurement of H2S and NO production in 
response to SNTX could possibly be done as more sensitive assays are developed. This 
will be able to give direct evidence that the gases are produced in response to SNTX. In 
addition, the use of more potent and selective CSE inhibitors would also confirm the 
biologic significance of H2S on vasorelaxation of precontracted aorta. The use of other 
blood vessels such as mesenteric artery beds (MAB) that exhibits 5-fold higher sensitivity 
to H2S as compared to the aorta (Cheng et al., 2004) can also be done to confirm SNTX’s 
vasorelaxing effects. As a representative peripheral resistance blood pressure, MAB 
makes more contribution in determining systemic blood pressure than aorta, a conduit 
artery. Therefore, the MAB may be a better choice for the study of the marked 
hypotension that SNTX causes.  
 
Other cellular components and mediators of SNTX’s vasorelaxing effect may also be 
studied. H2S has been found to relax blood vessels by opening K+ATP channels (Zhao et 
al., 2001; Cheng et al., 2004). Therefore, since H2S is involved in SNTX-induced 
vasorelaxation, K+ATP channels may also be a mediator of SNTX’s effect. The effect of 
L-cysteine and low molecular weight S-nitrosothiol intermediates on SNTX’s 
vasorelaxing effect can also be looked into.  In addition, besides H2S, the involvement of 
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other gases such as carbon monoxide as mediators of SNTX’s effect and their interaction 
with H2S and NO can also be investigated. Sulfur dioxide (SO2) for example, has been 
found to be a vasodepressor in the rat (Meng et al., 2003). 
 
Besides its effect on the vascular system, the effect of toxins such as SNTX on other 
smooth muscles of the gastrointestinal and respiratory systems etc would also be 
interesting as H2S has been shown to reduce spontaneous contractility of the rabbit ileum 
and inhibit electrically evoked contractions of the guinea-pig ileum and rat vas deferens 
(Teague et al., 2002). In addition, since the venom of S. horrida has been reported to 
cause inhibition of the uptake of choline and aminobutyric acid into rat brain 
synaptosomes and a concentration-dependent release of acetylcholine from rat brain 
synaptosomes, it may be worthwhile to study whether SNTX is responsible for this 
interference of the synthesis and release of neurotransmitters from their storage sites, and 
whether H2S and NO are involved as well. H2S has been found to be an endogenous 
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SNTX-α and SNTX-β are two subunits in SNTX that have been isolated, characterized 
and cloned from a Synanceja horrida venom gland cDNA library (Ghadessey et al., 
1996). The B30.2 domain of both SNTX-α and SNTX-β have been amplified by PCR 
using the appropriate primers in Table 18, and cloned into pGEX-5X-1 (Figure 44), 
producing pGEX-5X-1-αB30.2, pGEX-5X-1-βB30.2 respectively. The restriction 
enzymes used for the amplified B30.2 PCR products are Bgl II and Sal I while the pGEX-
5x-1 vector is cleaved with BamH I and Sal I. The recombinant vectors were transformed 
into E. coli BL21 (DE3). The use of αB30.2F-pGEX-5X-1 and βB30.2F-pGEX-5X-1 
primers with a thrombin cleavage site is an added attempt to cleave GST-αB30.2 and 
GST-βB30.2 fusion proteins more efficiently, as the Factor Xa cleavage site provided 





Table 17. Primers used in the amplification of the B30.2 domain of SNTX-α and SNTX-
β, to produce inserts which are then cloned into pGEX-5X-1. The additional thrombin 
cleavage site in αB30.2F-pGEX-5X-1 and βB30.2F-pGEX-5X-1 primers are underlined. 
Primers Sequences 
αB30.2F-pGEX-5X-1 5'-GCG CAG ATC TCA TGT GAC CTC ACC TTT GA-3' 
αB30.2F-pGEX-5X-1 
(with incorporation of 
thrombin cleavage site) 
5'-GCG CAG ATC TCA CTG GTT CCG CGT GGA TCT TGT 
GAC CTC ACC TTT GA-3' 
αB30.2R-pGEX-5X-1 5'-GCG CGT CGA CAT CGT GGT TAC CGG CAG GCC-3' 
βB30.2F-pGEX-5X-1 5'-GCG CAG ATC TCA TGT GAG CTC ACC CTG GA-3' 
βB30.2F-pGEX-5X-1 
(with incorporation of 
thrombin cleavage site) 
5'-GCG CAG ATC TCA CTG GTT CCG CGT GGA TCT TGT 
GAG CTC ACC CTG GA-3' 
βB30.2R-pGEX-5X-1 5'-GCG CGT CGA CAT CAT TGA CTT TCT GTT GTG-3' 
 
 
Figure 44. Vector map of pGEX-5X-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
